



**HAL**  
open science

# Emergence of Resistance to Atovaquone-Proguanil in Malaria Parasites: Insights From Computational Modeling and Clinical Case Reports

Gilles Cottrell, Lise Musset, Véronique Hubert, Jacques Le Bras, Jérôme Clain

► **To cite this version:**

Gilles Cottrell, Lise Musset, Véronique Hubert, Jacques Le Bras, Jérôme Clain. Emergence of Resistance to Atovaquone-Proguanil in Malaria Parasites: Insights From Computational Modeling and Clinical Case Reports. *Antimicrobial Agents and Chemotherapy*, 2014, 58 (8), pp.4504-4514. 10.1128/AAC.02550-13 . hal-02862980

**HAL Id: hal-02862980**

**<https://hal.science/hal-02862980v1>**

Submitted on 25 Jun 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **TITLE**

2  
3 **Emergence of resistance to atovaquone-proguanil in malaria parasites: insights from**  
4 **computational modeling and clinical case reports**

5  
6 Running title: Evolution of antimalarial drug resistance

7  
8 Gilles Cottrell<sup>1,2</sup>, Lise Musset<sup>3,4</sup>, Véronique Hubert<sup>5</sup>, Jacques Le Bras<sup>1,2,5</sup>, Jérôme Clain<sup>1,2,5</sup>, and the  
9 atovaquone-proguanil treatment failure study group<sup>6</sup>

10  
11 <sup>1</sup> UMR216, Institut de Recherche pour le Développement, 75006 Paris, France

12 <sup>2</sup> UMR216, Faculté de Pharmacie, Université Paris Descartes, Sorbonne Paris Cité, 75006, Paris,  
13 France

14 <sup>3</sup> Laboratoire de parasitologie, Institut Pasteur de Guyane, 97300 Cayenne, French Guiana

15 <sup>4</sup> Centre National de Référence du Paludisme, Laboratoire associé pour la région Antilles-Guyane,  
16 97300 Cayenne, French Guiana

17 <sup>5</sup> Centre National de Référence du Paludisme, Laboratoire de Parasitologie-Mycologie, AP-HP,  
18 Hôpital Bichat-Claude Bernard, 75018 Paris, France

19 <sup>6</sup> For a list of members please see the Acknowledgments

20  
21 **Corresponding authors:**

22 Jérôme Clain  
23 Address: UMR 216 IRD, Faculté de Pharmacie, Université Paris Descartes, 4 av de l'Observatoire,  
24 75006 Paris, France  
25 Tel: 00-33-1 70 64 94 33  
26 Fax: 00-33-1 53 73 96 17  
27 E-mail: [jerome.clain@parisdescartes.fr](mailto:jerome.clain@parisdescartes.fr)

28  
29 Gilles Cottrell  
30 Address: UMR 216 IRD, Faculté de Pharmacie, Université Paris Descartes, 4 av de l'Observatoire,  
31 75006 Paris, France  
32 Tel: 00-33-1 53 73 15 07  
33 Fax: 00-33-1 53 73 96 17  
34 Email: [gilles.cottrell@ird.fr](mailto:gilles.cottrell@ird.fr)  
35

36 **ABSTRACT**

37 The usefulness of atovaquone-proguanil (AP) as antimalarial treatment is compromised by the  
38 emergence of atovaquone resistance during therapy. However, the origin of the parasite mitochondrial  
39 DNA (mtDNA) mutation conferring atovaquone resistance remains elusive.

40 Here, we report a patient-based stochastic model that tracks the intra-host emergence of mutations in  
41 the multi-copy mtDNA during the few erythrocytic parasite cycles leading to the malaria febrile  
42 episode. The effect of mtDNA copy number, mutation rate, mutation cost and total parasite load on the  
43 mutant parasite load per patient was evaluated.

44 Computer simulations showed that almost any infected patient carried, after 4 to 7 erythrocytic cycles,  
45 de novo mutant parasites at low-frequency, with varied frequencies of parasites carrying varied  
46 numbers of mutant mtDNA copies. A large inter-patient variability in the size of this mutant reservoir  
47 was found, explained by the different parameters tested but also by the relaxed replication and  
48 partitioning of mtDNA copies during mitosis.

49 We also report seven clinical cases in which AP-resistant infections were treated by AP. These  
50 provided evidences that parasitocidal drug concentrations against AP-resistant parasites were  
51 transiently obtained within days following treatment initiation.

52 Altogether, these results suggest that each patient carries new mtDNA mutant parasites emerging  
53 before treatment and that are destroyed by high starting drug concentrations; however, because the size  
54 of this mutant reservoir is highly variable from patients to patients, we propose that some patients fail  
55 to eliminate all the mutant parasites, repeatedly producing de novo AP treatment failures.

56  
57

## 58 INTRODUCTION

59 The recent emergence of *Plasmodium falciparum* malaria resistance to artemisinins in Southeast Asia  
60 may lead to major public health consequences in a close future. There is an urgent need to identify  
61 treatment regimens that maximize the therapeutically useful life span of current antimalarial drugs (1).  
62 Among possible non-ACT available alternatives the role of atovaquone-proguanil (AP; initially  
63 licensed as Malarone<sup>®</sup>) has been questioned (2-4). Atovaquone-proguanil is a popular prophylactic  
64 drug and also shows high efficacy in the treatment of uncomplicated *falciparum* malaria in travellers.  
65 Recently it has been used in the Greater Mekong Subregion to treat individuals detected as *P.*  
66 *falciparum* carriers as part of a plan to contain artemisinin resistance (4). In addition, generic forms of  
67 Malarone<sup>®</sup> have been recently licensed, and the marketing and use of AP could increase in endemic  
68 settings (5).

69 Here, we focused on atovaquone resistance which develops easily during the treatment of  
70 uncomplicated *P. falciparum* malaria using atovaquone as monotherapy (6). This high failure rate  
71 prompted the introduction of the atovaquone-proguanil (AP) combination therapy. Atovaquone is a  
72 potent inhibitor of the cytochrome *bc1* complex or complex III in the mitochondrial electron transport  
73 chain (7). The addition of proguanil significantly increases the ability of atovaquone to collapse the  
74 mitochondrial membrane potential (8), and also generates in vivo the metabolite cycloguanil which  
75 antagonizes the parasite dihydrofolate reductase (*dhfr*) in the folate pathway (9-10). Resistance of *P.*  
76 *falciparum* to atovaquone is primarily determined by one point mutation in the mitochondrial and  
77 multi-copy *cytochrome b* (*cytb*) gene (11-12) which encodes a subunit of the cytochrome *bc1* complex.  
78 In addition, *P. falciparum* parasites harbouring *dhfr* mutations exhibit cross resistance to both  
79 antifolates pyrimethamine and cycloguanil (9, 13-14). Nowadays, a high rate of antifolate resistance is  
80 found in *P. falciparum* parasites across major endemic areas (15). Hence, infecting parasites often  
81 carry antifolate resistance and just a single evolutionary step –the acquisition of the *cytb* mutation– is  
82 sufficient to make parasites resistant to both cycloguanil and atovaquone. Despite that the atovaquone  
83 resistance mutation is not detected in endemic areas (16-18), about 1 in 100 non-immune travellers  
84 returning to the UK and who took AP as treatment to cure a *P. falciparum* malaria episode had  
85 treatment failure associated with atovaquone resistance (19). Genetic studies suggest that the  
86 atovaquone resistance mutation evolves *de novo* during the primary infection or its treatment, being  
87 then selected by AP treatment (20-22).

88 However, the mechanism underlying the rapid evolution of the *cytb* mutant parasites during AP  
89 treatment remains elusive. Various hypotheses suggest a role for an increased rate of mitochondrial  
90 DNA (mtDNA) mutations induced by atovaquone (23) and for pharmacokinetic-pharmacodynamic  
91 considerations (5). Here another explanation was considered for the intra-host acquisition of  
92 atovaquone resistance. We hypothesize that the multiple mtDNA copies per parasite along with the  
93 complex replication of mtDNA (24-25) could favour a large mutational input before treatment.  
94 Addressing experimentally the intra-host dynamics of mtDNA mutations is currently not possible in

95 the *P. falciparum* model, mainly because of its intractability, and modeling offers an opportunity to  
96 explore this question.  
97 Therefore, we developed for the first time a patient-based stochastic model that tracks the intra-host  
98 emergence of malarial mtDNA mutations during the few rounds of asexual blood  
99 stage reproduction leading to the malaria febrile episode and diagnosis. Briefly, it describes the  
100 appearance of spontaneous mtDNA mutations and their propagation within replicating mitochondrial  
101 genomes and parasites according to intra- and inter-cellular random drift, in absence of drug selection.  
102 We evaluated the effect of several parameters on the intra-host frequency of mtDNA-mutated  
103 parasites: the mtDNA mutation rate, the fitness cost associated to the mtDNA mutation, the number of  
104 mtDNA copies per parasite, and the total parasite load per patient. Then, we reported clinical  
105 evidences showing for the first time how AP-resistant parasites responded to AP treatment. Finally,  
106 we integrated these computational and clinical new findings to propose a mechanistic framework  
107 describing how atovaquone resistance emerges during malaria blood stages and how it translates into  
108 AP treatment failure, and we discuss the implications of these results for drug usage in the field.

## 109 MATERIAL AND METHODS

110 We used a two-stage process: 1) we developed a model to calculate the probability that new mtDNA  
111 mutations will be present among the malaria parasites at the time of treatment initiation; and 2) we  
112 evaluated whether any such mtDNA-mutated parasites could survive AP treatment and recrudescence as a  
113 new resistant infection. This two steps strategy follows a similar logic as the one used for nuclear  
114 genes encoding resistance (26).

115 **1) The model.** The mathematical description of the model is provided in the Supplementary Text.

116 **Model framework.** The model simulates the replication and partitioning of parasitic mitochondrial  
117 genomes within a replicating blood stage parasite lineage. It tracks the production and propagation of  
118 parasite mtDNA mutations within a single infected human host, starting from the delivery of hepatic  
119 parasitic forms into the blood to the time at which the patient will seek for medical care and treatment.  
120 We assumed that: the infection takes place in a non-immune host; all parasites delivered from  
121 hepatocytes into the blood have the wild type mitochondrial genotype; the mutation is a single  
122 nucleotide replacement that arises through random and recurrent mtDNA replication errors during the  
123 erythrocytic asexual parasite growth.

124 **Parasite growth.** We assumed that all initial parasites originated from a single release from the liver  
125 and that each parasite infected a single erythrocyte. In each infected erythrocyte, the nuclear and  
126 mitochondrial genomes of the parasite each are replicated through five consecutive endo-mitosis  
127 (within one parasite cell) during one erythrocytic 48h-cycle, eventually leading to 32 daughter  
128 parasites. Upon egress from the erythrocyte, each daughter parasite released in the blood has a  
129 probability  $p_{\text{surv}}$  to survive and initiate a new erythrocytic cycle. We assumed parasite growth and  
130 cycles to be synchronous within a single host infection.

131 **Replication and partitioning to daughter cells of mitochondrial genomes.** The detailed  
132 mechanisms by which malaria mitochondrion and its genome replicate and are passed to daughter cells  
133 are largely unknown, although important features have been described (24, 27). Hence we used a  
134 sequence of events with minimum mechanistic assumptions. Eukaryotic organelle genomes, such as  
135 mtDNA, undergo *relaxed* replication and partitioning, as compared to the stringent nuclear genome  
136 (25, 28); it means that multiple mtDNA copies are replicated and partitioned randomly, with respect to  
137 genotype.

138 We assumed that: i) each parasite contains one mitochondrion (29); ii) one mitochondrion  
139 contains  $n$  copies of its genome (24); iii)  $n$  is constant within an infection; iv) at each mtDNA  
140 replication, the template copies to be duplicated will be selected by  $n$  random draws with replacement  
141 – allowing some mtDNA copies to be replicated several times while other copies not to be replicated.  
142 This leads to a parasite containing one mitochondrion with  $2n$  mtDNA copies; v) the mitochondrion  
143 containing  $2n$  mtDNA copies is then partitioned into two independent mitochondrial units, each  
144 containing  $n$  mtDNA copies selected at random among the  $2n$  mtDNA copies; vi) the  
145 duplication/partitioning cycle of the mitochondrial genome repeats five times during one erythrocytic

146 48h-cycle; then, each of these  $2^5=32$  mitochondrial units will constitute the single mitochondrion of  
147 one of the 32 daughter parasites; vii) the resistance mutation arises spontaneously in one mtDNA copy  
148 with a probability  $\mu$  (per nucleotide per replication); because the atovaquone resistance mutation is a  
149 single nucleotide substitution, we assumed that the probability of a resistant mutation to appear equals  
150 the per nucleotide mitochondrial mutation rate ; during the course of the erythrocytic phase, n different  
151 mutant parasite genotypes can be produced within a single host: parasites having from 1 to n of their n  
152 mtDNA copies mutated.

153 We did not consider back mutation because its effect is unlikely to alter significantly the intra-host  
154 frequency of the resistance mutation, specifically on the short time scale that our study addresses (1 to  
155 7 cycles of 48hr intra-erythrocytic growth).

156 **Parasite definition according to mitochondrial genotype.** i) parasites having none of their n mtDNA  
157 copies mutated were defined as *wild type* ; ii) parasites having from 1 to n-1 of their n mtDNA copies  
158 mutated were defined as *heteroplasmic*; iii) parasites having all of their mtDNA copies mutated were  
159 defined as *homoplasmic-mutant*; iv) the grouping of both heteroplasmic and homoplasmic-mutant  
160 parasites was defined as *all-mutant* parasites.

161 **Mutation cost and fitness.** In some simulations, we assumed that, in absence of drug, carrying the  
162 resistance mutation results in decreased parasite fitness (12, 30-31). We defined the fitness as the  
163 proportion of daughter parasites of a given mitochondrial genotype that will succeed in invading new  
164 erythrocytes. However, the mutation does not alter the probability of a mutant mtDNA copy to be  
165 replicated or partitioned (25). In addition to the neutral situation (no decrease in fitness associated to  
166 the mutation), two other situations were considered. First, the mutation is recessive relative to the  
167 decrease in fitness: only homoplasmic-mutants have a decreased survival probability when compared  
168 to any other genotype. Second, the mutation is dominant relative to the decrease in fitness: the survival  
169 probabilities of heteroplasmic and homoplasmic-mutants are the same, and lower than the one of wild  
170 type parasites. The recessive and dominant effects explored here represent the two ends of a spectrum,  
171 in which the parasite fitness would be a function of the number of mutated mitochondrial genes.

172 **Input parameters.** i) the number of parasites delivered into the blood after the hepatic phase:  $x =$   
173  $5 \times 10^4$  ; ii) the mtDNA mutation rate:  $\mu = 10^{-9}$ ,  $10^{-10}$ , and  $10^{-11}$ /nucleotide/replication. To our  
174 knowledge, there is no direct and unbiased estimate for the probability of a mtDNA change per  
175 nucleotide per mtDNA replication in *P. falciparum*. Therefore, we have used very conservative values  
176 based on values estimated in other species which range from  $0.7 \times 10^{-8}$  to  $17 \times 10^{-8}$ /nucleotide/mtDNA  
177 replication (with one DNA replication/cell division (32-35)). In *P. falciparum* the nuclear mutation  
178 rate was estimated to be  $1.7 \times 10^{-9}$ /nucleotide/48hr-generation during the blood stage growth (36); iii)  
179 the parasite survival probability associated with the distinct mitochondrial genotypes (12, 37): wild  
180 type,  $p_{\text{surv}} = 12/32$ ; homoplasmic-mutant,  $p_{\text{surv}_m} = 6/32$ ; heteroplasmic,  $p_{\text{surv}_{ht}} = 12/32$   
181 when the mutation cost is recessive and  $p_{\text{surv}_{ht}} = 6/32$  when it is dominant; iv) the number  
182 of mtDNA copies/parasite:  $n = 5, 10, 20,$  and  $40$ . This copy number was estimated to be about 20

183 copies/cell for *P. falciparum*, based on the analysis of a single parasite strain (24); v) the number of  
184 erythrocytic 48h-cycles following delivery from the liver: from 1 to 7 (this corresponds from 2 to 14  
185 days after the hepatic phase ; the median delay between onset of symptoms and treatment is 4 days in  
186 imported *falciparum* malaria (38)).

187 **Model simulations.** Varying parameters were the mtDNA copy number, the mutation rate, the  
188 mutation cost, and the number of erythrocytic 48h-cycles following parasite delivery from the liver.  
189 Other parameters were fixed. For each combination of parameters tested, 20,000 simulations were run.  
190 The simulations have been performed with R v 2.12.2 (R Foundation for Statistical Computing,  
191 Vienna, Austria).

192 **2) Clinical case reports.** The French malaria reference center database was searched for late AP  
193 treatment failures in which the recrudescence infections were treated again with AP. A total of 6,247  
194 imported *P. falciparum* infections diagnosed and treated in France with AP were recorded by the  
195 French malaria reference center, 2002-2012. Basic demographic and epidemiologic data, clinical and  
196 parasitological informations, treatment, and history of travel and of malaria infections were collected  
197 systematically. Pre- and post-treatment blood isolates were sent to the French malaria reference center  
198 by French hospitals participating in the sentinel network for drug resistance and plasma drug testings.  
199 Analyzed samples were obtained by blood collections required by the standard medical care for all  
200 patients presenting with fever upon hospital admission in France.

201 **3) Ethics statement.** According to the French legislation, bio-banking and secondary use for scientific  
202 purpose of human clinical remaining samples are possible as long as the corresponding patients are  
203 informed and has not given any objection to them. Here, this requirement was fulfilled as the  
204 information is given to every patient through the Hospital notice entitled “Information for patients”,  
205 and no immediate or delayed patient opposition was reported by the hospital clinicians to the French  
206 malaria reference center. Moreover, samples received at the French malaria reference center have been  
207 registered and declared for research purpose as a bio-bank to both the Assistance Publique des  
208 Hôpitaux de Paris and to the French National Institute of Health Survey. No institutional review board  
209 approval is required according to the French legislation (article L. 1111-7 du Code de la Santé  
210 Publique, article L. 1211-2 du Code de Santé Publique, articles 39 et suivants de la loi n° 78-17 du 6  
211 janvier 1978 modifiée en 2004 relative à l’informatique, aux fichiers et aux libertés). Samples used  
212 were not anonymized.

213 **4) Molecular analysis.** Parasite genomic DNA was extracted from whole blood, thin or thick blood  
214 smears, and plasma. The *cytb* gene was sequenced directly from PCR products to genotype the codon  
215 *cytb*<sup>268</sup> that associates with atovaquone resistance. Five nuclear microsatellite locus (TAA81, TAA87,  
216 PfPK2, Ara2, and TAA60) dispersed on 5 different *P. falciparum* chromosomes were genotyped by  
217 capillary electrophoresis to determine the nuclear genetic background associated with each of these  
218 parasite isolates. All methods were as previously described (22). The codons 51, 59 and 108 of the



219 *dhfr* gene associated with cycloguanil resistance were genotyped either by PCR-RFLP as described in  
220 (39) or by direct sequencing of PCR products.

221 **5) Estimation of the parasite reduction ratio for atovaquone-proguanil/cycloguanil-resistant**  
222 **parasites.** To evaluate the intrinsic *in vivo* efficacy of AP treatment on drug resistant parasites, we  
223 measured the parasite reduction ratio (PRR) which is defined as the fractional reduction in parasite  
224 number per asexual life cycle (i.e. 48h) or time unit (day) during the treatment (40). The parasite  
225 reduction ratio is similar to the killing rate induced by a specific treatment. A parasite reduction ratio  
226 of 50 means that 1 out of 50 parasites survive to drug treatment per asexual life cycle. Based  
227 on the clinical cases in which infected patients carrying AP-resistant parasites were treated with AP  
228 and for which two non-negative and consecutive blood parasite counts were recorded, we estimated  
229 the PRR as being equal to  $(P_0/P_t)^{2/t}$ , where  $P_0$  and  $P_t$  are parasite loads at days 0 and t, respectively (41-  
230 42).

231 **6) Estimation of the minimum time required to clear all the cryptic *de novo* mutant parasites**  
232 **from an infection.** Using the intra-host distribution of mtDNA-mutated parasites generated through  
233 20,000 simulated infections, we estimated the minimum time (T, in days) during which blood drug  
234 concentrations should equal or exceed the minimum parasitocidal concentration ( $MPC^{APR}$ ) to clear all  
235 the cryptic mtDNA-mutated parasites. We assumed that the PRR of AP-resistant parasites ( $PRR^{APR}$ ) is  
236 constant and that AP-resistant parasites are killed at the same rate whether they represent the minority  
237 or the dominant population within the infection. An estimate for T can be obtained using the following  
238 formula:  $T = 2 \times \ln B_m / \ln(PRR^{APR})$ , where  $B_m$  is the mutant parasite load per infection (41). We  
239 estimated T for simulations obtained with a recessive fitness cost, copy number = 20 and mutation rate  
240 =  $10^{-10}$ /nucleotide/replication.

241

## 242 RESULTS

243 **A model of mtDNA evolution for the pre-treatment phase.** We modeled the evolution of *de*  
244 *novo* mtDNA mutations that arose during the intra-host expansion of replicating *P.*  
245 *falciparum* erythrocytic forms in the absence of drug selection. After the delivery of parasites from the  
246 liver into the blood stream, the mean total parasite load per patient multiplied by ~12-  
247 times/erythrocytic 48hr-cycle and reached about  $1.5 \times 10^{11}$  parasites at the 6<sup>th</sup> cycle (corresponding to  
248 12 days after the hepatic phase). Assuming a volume of 5 liters of blood per patient and an erythrocyte  
249 concentration of  $5 \times 10^{12}/L$ , this translates to 0.6% of total host erythrocytes being infected. During this  
250 intense replicating phase, random recurrent mtDNA mutations occurred and then replicated and  
251 segregated according to random drift (combined or not with negative selection) within daughter  
252 mitochondrial genomes and parasites (Fig. 1). This produced heteroplasmic parasites and ultimately  
253 homoplasmic-mutant parasites, having all of their mtDNA copies being mutated (Fig. 1A). For our  
254 reference model (neutral mutation, 20 mtDNA copies per parasite, and a mtDNA mutation rate of  $10^{-10}$ /  
255 nucleotide/replication), all-mutant parasites (having at least one mtDNA copy being  
256 mutated) appeared on average at the first erythrocytic cycle with a mean frequency of  $\sim 4 \times 10^{-9}$  all-  
257 mutant parasites/infection which then slightly increased with additional 48hr-cycles to reach  $\sim 75$  times  
258 the mutation rate at the 6<sup>th</sup> cycle (Fig. 1B). Homoplasmic-mutant parasites appeared on average at the  
259 3<sup>rd</sup> cycle and then increased in frequency to a mean value close to the mutation rate at the 6<sup>th</sup> cycle  
260 (Fig. 1B). At the 6<sup>th</sup> cycle the composition of the mtDNA mutant parasite population per patient was  
261 found to be complex, each patient harbouring at varied and low frequencies an array of genotypically  
262 distinct mutant parasites defined by the number of mtDNA copies being mutated (Fig. 1C and 1D).  
263 Next, we focused on the intra-host distribution of mutant parasites at the 6<sup>th</sup> cycle when the mean total  
264 parasite load per patient was  $\sim 1.5 \times 10^{11}$ . The number of mtDNA copies per parasite had opposite  
265 effects on the intra-host distribution of homoplasmic- and all-mutant parasite load (Fig. 2A and 2B):  
266 the larger the copy number, the larger is the number of all-mutants but the lower is the number of  
267 homoplasmic-mutants per infection. The size of both the homoplasmic- and all-mutant populations  
268 increased with the mutation rate (Fig. 2C and 2D) and with the total parasite load per  
269 patient (Fig. 2E and 2F). Finally, the fitness cost of the resistance mutation altered the number of  
270 mutant parasites per infection in a very expected way when compared to a neutral  
271 model (Fig. 2G and 2H): a recessive mutation cost did not alter the all-mutant population but was  
272 associated with a slight decrease in the number and the variability of the homoplasmic-mutant  
273 population, whereas a dominant mutation cost markedly decreased both all- and homoplasmic-mutant  
274 population size. Simulations also revealed as a general trend the right skewed distribution of mutant  
275 parasites per infection (Fig. 1D and Fig. 2). Highly relevant to the outcome of malaria treatment,  
276 infections containing mutant parasites before treatment were extremely frequent (Fig. 3): even when  
277 considering a conservatively low mtDNA mutation rate of  $10^{-10}$ /nucleotide/replication and parasite  
278 burden of  $1.2 \times 10^{10}$ /body ( $\sim 0.05\%$  of total host erythrocytes being infected), 100% of simulated

279 infections contained at least one parasite having at least one mtDNA copy being mutated  
280 (corresponding to the 5<sup>th</sup> cycle in Fig 3A; this proportion decreased to 93% for 10<sup>9</sup> parasites per host).  
281 Infections containing at least one homoplasmic-mutant parasite were also frequent: 1.4%, 16.3%, and  
282 88.3% at the 5<sup>th</sup>, 6<sup>th</sup> and 7<sup>th</sup> cycle, respectively. The proportion of patients carrying high loads of  
283 mutant parasites was largely altered by the total parasite load per patient (Fig. 3A and 3B).  
284 In summary, whatever the parameter values tested here, all simulations shared three essential  
285 results: 1) the mtDNA resistance mutation could occur *de novo* and propagate in most infected host  
286 during the erythrocytic parasite expansion phase before a treatment has been initiated; 2) each  
287 patient harboured a complex reservoir of cryptic mutant parasite populations, with varied frequencies  
288 of parasites having varied numbers of their mtDNA copies being mutated ; 3) a marked inter-patient  
289 variation in the size of this cryptic mutant reservoir was found, even for a unique set of parameters;  
290 and 4), a small fraction of the patients carried a high load of mutant parasites. The very high rate of  
291 patients found to carry mtDNA-mutated parasites would suggest a very high rate of AP treatment  
292 failure, unless the current AP regimen retains therapeutic efficacy towards mtDNA-mutated parasites,  
293 thereby limiting the extent of treatment failure. Therefore we sought for evidences showing how AP-  
294 resistant parasites responded to AP therapy.

295 **How do atovaquone-proguanil/cycloguanil-resistant parasites respond to AP treatment: clinical**  
296 **observations.** Within the ~6,200 *P. falciparum* imported malaria cases that were treated with AP and  
297 reported to the French malaria reference center between 2002 and 2012, we identified 7 cases in which  
298 recrudescing AP-resistant infections were treated again with AP (Table 1). Full case reports are  
299 described in Supplementary Text. These clinical observations were backed up with the genotyping of  
300 atovaquone and cycloguanil resistance markers and of microsatellites to assess the identity of the pre-  
301 treatment and post-treatment recrudescing parasites. For each patient, the genetic data showed the  
302 selection after the first AP treatment of mutant *cytb*<sup>268</sup> parasites having a nuclear genetic background  
303 identical to the one of parasites from the primary infection. This is consistent with our earlier findings  
304 (11-12). For five of these patients (patients P1 to P5) the treatment of the AP-resistant infections with  
305 another cure of AP was associated with a late failure with parasites recrudescing 8 to 30 days after  
306 therapy initiation (mean: 20.6 days), whereas for the other two patients the treatment was altered at  
307 day 3 and 5 although their initial parasitemia had significantly decreased. For five cases (P3 to P7),  
308 evidence for AP-resistant parasite clearance within days following treatment was obtained from  
309 microscopic examination of blood smear, and for three cases (patients P1, P4 and P7) no standard  
310 antimalarial drug in addition to atovaquone, proguanil, and cycloguanil was detected in the blood  
311 during treatment (these informations were not available for the other cases).  
312 Based on the patients P3, P6, and P7 for which two non-negative and consecutive blood parasite  
313 counts were available (at day-0 and day-3 or day-5; table 1), we estimated the parasite reduction ratio  
314 for AP-resistant infections (PRR<sup>APR</sup>) during the first days of AP therapy to be 116, 10, and 30 (mean:  
315 52), respectively. Altogether, these clinical findings showed that some AP-resistant parasites can be

316 eliminated by AP as long as drug blood concentrations are maintained above a yet unknown threshold  
317 value, which we defined as the minimum parasiticidal concentration ( $MPC^{APR}$ ).

318 **Estimation of the minimum time required to clear the cryptic mtDNA-mutated parasites.** We  
319 estimated the time (T) during which drug concentrations in the blood should exceed or equal the  
320  $MPC^{APR}$  to clear from any host all the cryptic mutant parasites that emerged during the primary  
321 infection. Assuming a constant  $PRR^{APR}$  of 50,  $T = 0.51 \ln B_m$  (where  $B_m$  is the mutant parasite load per  
322 patient). In hyperparasitemic patients carrying about  $1.8 \times 10^{12}$  parasites (~7% of total host erythrocytes  
323 being infected), the maximum load of homoplasmic-mutant parasites found before treatment among  
324 20,000 simulations was 176,395 parasites/host (simulation parameters: recessive mutation, mutation  
325 rate =  $10^{-10}$ /nucleotide/replication, mtDNA copy number = 20). The  $MPC^{APR}$  should then be  
326 maintained during at least 6.2 days to ensure the complete elimination of this homoplasmic-mutant  
327 intra-host population (Table 2). When considering mutant parasites having at least 1/20 or 10/20 of  
328 their mtDNA copies being mutated, drug blood concentrations equal to or larger than the  $MPC^{APR}$   
329 should be maintained during a longer length of time to produce similar treatment efficacy. In non  
330 hyperparasitemic patients (for example carrying about  $1.5 \times 10^{11}$  or  $1.2 \times 10^{10}$  parasites which correspond  
331 to ~0.6% and ~0.05% of total host erythrocytes being infected), the  $MPC^{APR}$  should be maintained for  
332 shorter time to clear all the mutant parasites (Table2).

333

## 334 DISCUSSION

335 We report here new findings that help to explain the easy and repeated evolution of mtDNA mutations  
336 conferring atovaquone resistance and the high rates of atovaquone and AP treatment failures in non or  
337 little immune patients (6, 19, 21, 43). Firstly, our work explores for the first time the intra-host  
338 dynamics of malarial mtDNA mutations through stochastic modeling at the micro-evolutionary time  
339 scale, id est during few erythrocytic parasite cycles. Computational data show that almost any primary  
340 malarial infection in a non-immune human host carries a cryptic population of *de novo* mtDNA-  
341 mutated parasites at the time of malaria diagnosis, before a treatment has been initiated. Given the  
342 large parasite load per human body at malaria diagnosis (the median peripheral parasitemia of 0.4% in  
343 travellers roughly corresponds to  $1.2 \times 10^{11}$  parasites per body) and that each parasite contains  $\sim 20$   
344 copies of mtDNA (24), the intra-host population size of mtDNA molecules grows to extremely large  
345 values. This provides multiple opportunities for random mtDNA mutations to occur within each  
346 infected host. The extremely low intra-host frequency of these *de novo* mtDNA mutations ( $\sim$  a median  
347 of 1 to 10 times the mutation rate, according to total parasite load per patient, Table S1) precludes their  
348 detection in patient blood samples with standard molecular techniques. Indeed, in hyperparasitemic  
349 patients carrying  $\sim 1.8 \times 10^{12}$  parasites and assuming 5 liters of blood per patient, the model indicated  
350 that a mutant allele is present at an intra-host median frequency of  $\sim 10^{-9}$  (simulation parameters:  
351 recessive mutation, mutation rate =  $10^{-10}$ /nucleotide/replication, mtDNA copy number = 20) which  
352 translates to  $\sim 3$  mutant allele copies/10 mL of blood (this increased to 36 allele copies/10 mL of blood  
353 in top 1% of patients with high mutant parasite burden). This is consistent with genetic tests that failed  
354 to detect the resistance mutation in the pre-treatment blood samples (19-21, 44-45), even using a  
355 mutant-enrichment method (22). Highly sensitive methodologies based on next-generation sequencing  
356 which can detect one mutant copy among about  $10^6$ - $10^7$  wild-type copies could be helpful in the future  
357 to test our computational results (46-47). In summary, the model findings point to spontaneous  
358 mtDNA mutations occurring before treatment as a primary source of atovaquone resistance mutations.  
359 And we consider it is not necessary to invoke a mutagenic effect of atovaquone (see Supplementary  
360 Text for further discussion). This proposal is in line with findings in *Mycobacterium tuberculosis*  
361 reporting the *de novo* acquisition of multidrug resistance before treatment as a risk factor for treatment  
362 failure (48), and with mathematical modeling studies in several pathogens (48-51). Secondly, we  
363 report novel clinical cases showing that the drug blood concentrations attained during the first days of  
364 AP therapy are high enough to clear some AP-resistant parasites. We provide an estimate for the  
365  $PRR^{APR}$  (mean: 52 ; see Supplementary Text for discussion associated with this estimate), not  
366 markedly different from the values obtained for AP-sensitive infections which ranged from 46 to 261  
367 in non-immune adults (52). The reasons for this finding remain elusive but we propose several  
368 hypotheses. At high concentrations, atovaquone can inhibit both wild type and mutant cytochrome *b*  
369 (12) and was found also to be a more general ubiquinone antagonist, inhibiting the substrate-  
370 ubiquinone reductases of the respiratory chain distinct from the cytochrome *bcl* complex (53). In

371 addition, it is the net effect on parasite killing of high concentrations of atovaquone, proguanil and  
372 cycloguanil in combination that should be considered, an issue raised recently also for chloroquine  
373 (54). An estimate for the  $MPC^{APR}$  is yet to be determined and the  $MPC^{APR}$  will likely be a complex  
374 interplay between atovaquone, proguanil and cycloguanil blood concentrations and the threshold  
375 number of mutated mtDNA copies per parasite that confers resistance to atovaquone.  
376 Altogether, our computational and clinical results support the following *scenario* regarding *de novo*  
377 AP treatment failures. AP treatment success relies in almost any patient on the clearance of cryptic  
378 mtDNA-mutated parasites that evolved during the erythrocytic growth phase of the primary infection.  
379 Clearance of mutants must occur within the first days of AP treatment, when drug blood  
380 concentrations are the highest and exceed the  $MPC^{APR}$ . We then refer to the time during which drug  
381 blood concentrations exceed or equal the  $MPC^{APR}$  as the window of mutant prevention. We suggest  
382 that the therapeutic margin of the current AP regimen, especially in the context of non-supervised  
383 treatment, is not wide enough to clear all the cryptic mutant parasites in any patient, hence producing  
384 repeatedly *de novo* AP treatment failures. The main reasons for this, based on our data and the  
385 literature, could be the inter-patient variability of the following parameters: the width of the mutant  
386 prevention window and the number of *de novo* mtDNA-mutated parasites that the treatment has to  
387 destroy. With regards to the width of the mutant prevention window, a major source of variability is  
388 obviously the large inter-patient variability in atovaquone blood concentration which is driven by the  
389 slow and limited absorption of the drug (55-56). In addition, this is likely made worse in the context of  
390 non-supervised treatment because of potential vomiting and/or poor compliance with the 3-day course  
391 of treatment. Another source of variability could be the level of atovaquone resistance conferred by the  
392 *cytb*<sup>268</sup> mutation which will likely alter the  $MPC^{APR}$ , hence the width of the mutant prevention window.  
393 With regards to the *de novo* mutant parasite load, the model revealed a very large inter-patient  
394 variability. This variability was contributed largely by some type of random drift specifically  
395 associated with mtDNA replication and partitioning during mitosis and also by the inter-patient  
396 variability in total parasite load at diagnosis. As shown also by modeling studies for nuclear mutations  
397 (51, 57), the larger is the total parasite load, the larger the *de novo* mutant load, and the longer it will  
398 take to eliminate all *de novo* resistant parasites from an infection. This is consistent with our clinical  
399 data and those already published (19-21, 45, 58-60), which altogether showed that 17 of 20 patients  
400 experiencing *de novo* AP treatment failure presented with parasitemia at diagnosis close to or larger  
401 than 0.4% (corresponding to the median peripheral parasitemia observed at the time of *P. falciparum*  
402 malaria diagnosis in travellers returning to France and the UK (38, 61); mean parasitemia: 2.4%,  
403 median: 1.4%, min: <0.005%, max: 13%; Table S2). Controlled studies will be needed to confirm this  
404 observation. Additional sources of mutant load variability could be contributed by the mtDNA  
405 mutation rate (48, 62) and mtDNA copy number, but whether those parameters vary substantially  
406 between *P. falciparum* clinical isolates remains to be established.

407 Here, we did not consider mutations occurring earlier during the primary infection, *id est* during the  
408 liver phase (63). This would however even increase the mutant load and the probability of a patient to  
409 carry mutant parasites. Regarding the physical mechanisms controlling how malaria organelles and  
410 their genome replicate and are passed to daughter cells, this remains a largely unexplored area. During  
411 one erythrocytic 48hr-generation, the malarial mitochondrion elongates from a single organelle, then  
412 branches and ultimately divides to create multiple daughter organelles (27). Our model assumes 5  
413 consecutive rounds of random mtDNA replication/partitioning during one erythrocytic generation, in  
414 which each mtDNA copy behave as an independent unit of replication. We argue that this model  
415 mimics the effects of both the likely separation of mtDNA molecules within the elongating and  
416 branching mitochondrion and the random drift associated with the mtDNA replication (24-25, 27).  
417 Variations of this standard model can be envisaged, such as a more panmictic behaviour of mtDNA  
418 copies (24), but we do not expect they will produce qualitatively very different results. In its current  
419 version, our model is not designed to evaluate the long term evolution of mitochondrial genetic  
420 diversity, either within a single-host infection that would last for several weeks or months or within an  
421 entire malaria parasite population across multiple rounds of host/vector transmission. This would  
422 require to consider back mutation and host-specific immunity and to take into account the large  
423 heterogeneity and complexity of parasite transmission (26, 64). Altogether, our model provides, to our  
424 knowledge, the first framework to study the intra-host early evolution of malarial mtDNA mutations.  
425 It may provide a valuable addition to the current modeling methodologies that rather focus on nuclear  
426 mutations. Specifically, it could be helpful to study the evolution of mitochondrial genes whose  
427 products may be targeted by new antimalarial drugs, an area of intense research (65-68).

428 It is currently not clear how many mutant *cytb* copies per parasite are necessary to confer high-grade  
429 atovaquone resistance. Our model did not simulate the fate of parasites having distinct mtDNA  
430 genotypes (wild type, heteroplasmic, homoplasmic-mutant) once treatment has been initiated, hence  
431 under drug selection. Experiences in yeast show that the effect of drug selection will largely  
432 overshadow the one of random drift (69). We speculate that once AP treatment has started,  
433 intercellular selection within the host will likely favour the growth of those parasites having the largest  
434 proportions of their mtDNA copies being mutated. In case some heteroplasmic genotypes could  
435 survive to AP treatment, the combination of random drift and strong drug selection would result in a  
436 progressive shift in the mutant parasite population, with the progressive accumulation of  
437 homoplasmic-mutant parasites (as shown experimentally in yeast (69); see also Supplementary Text).

438 Our model for the emergence of atovaquone resistance suggests that the partner drug -here proguanil  
439 together with its active metabolite cycloguanil- plays a critical role in preventing the escape of *de novo*  
440 mtDNA mutant parasites. This is consistent with the observation that most atovaquone resistance  
441 mutations reported to date were found to emerge in parasites carrying a mutant *dhfr* gene (Table S2).

442 Controlled studies with a large patient cohort will be necessary to confirm these observations.  
443 Speculating on the computational model findings and the high rate of *de novo* AP treatment failure  
444 reported in travellers, we warn against the risk of the rapid emergence of atovaquone resistance if AP  
445 is used massively with the current regimen in transmission areas where people are little- or non-  
446 immune (2-3). This could be particularly rapid in the multiple areas where mutant *dhfr* gene is found  
447 at a high rate in parasite populations (15), as a consequence of a long history of sustained use of the  
448 antifolate pyrimethamine.

449 The framework proposed here suggests several ways by which to delay the clinical emergence of AP  
450 resistance. A first strategy could be to extend the window of mutant prevention by maintaining  
451 atovaquone and proguanil/cycloguanil blood concentrations at a higher level and for a longer period of  
452 time than those achieved with the current AP dosage regimen. The benefit of a more aggressive  
453 chemotherapy in reducing the chance of *de novo* resistance selection has been recently questioned (1,  
454 70). However, the clinical findings that AP at high drug blood concentrations remains potent on AP-  
455 resistant parasites suggest such a strategy merits further attention. A second (and possibly  
456 complementary) strategy that we favour would be to minimize the number of *de novo* mutant parasites  
457 that AP has to destroy. This could be achieved through combination therapy, employing an additional  
458 drug equally potent against AP-sensitive and AP-resistant parasites. For example, the triple  
459 combination of artesunate-atovaquone-proguanil proved to be very efficient for the treatment of  
460 malaria in pregnancy and of uncomplicated malaria (71-73). Also, the use of AP could be restricted to  
461 treat infections from endemic areas where the frequency of mutant *dhfr* genes is low. Finally, an  
462 important prediction of our model is that patients with higher parasite burden at diagnosis face an  
463 increased risk for carrying larger *de novo* mutant parasites. Then the use of AP as treatment could be  
464 restricted to patients with lower parasitemia at diagnosis.

465 In summary, we report new computational and clinical findings describing the intra-host evolution of  
466 mtDNA mutations conferring atovaquone resistance. The mechanistic framework proposed here helps  
467 to explain the repeated evolution of *de novo* AP resistance, and it could help policy makers in  
468 designing AP-containing treatment regimens that delay the clinical emergence of atovaquone  
469 resistance.



470 **ACKNOWLEDGMENTS**

471 We thank Vivien Le Bras, Selva Pillai and Sophie Adjalley for critical reading of the manuscript, and  
472 Olivier Tenaillon for helpful discussions. The co-authors included in the atovaquone-proguanil  
473 treatment failure study group consist of: Sandrine Houzé (Centre National de Référence du Paludisme,  
474 Laboratoire de Parasitologie-Mycologie, AP-HP, Hôpital Bichat-Claude Bernard, 75018 Paris), Céline  
475 Maréchal (Centre National de Référence du Paludisme, Laboratoire de Parasitologie-Mycologie, AP-  
476 HP, Hôpital Bichat-Claude Bernard, 75018 Paris), Pascal Houzé (Laboratoire de Biochimie, AP-HP,  
477 Hôpital Saint Louis, 75010 Paris), Marc Thellier (Centre National de Référence du Paludisme,  
478 Laboratoire de Parasitologie-Mycologie, AP-HP, Hôpital La Pitié-Salpêtrière, 75013 Paris), Eric  
479 Kendjo (Centre National de Référence du Paludisme, Hôpital La Pitié-Salpêtrière, 75013 Paris),  
480 Liliane Ciceron (Centre National de Référence du Paludisme, Hôpital La Pitié-Salpêtrière, 75013  
481 Paris), Sophie Matheron (Maladies infectieuses et tropicales, AP-HP, Hôpital Bichat-Claude Bernard,  
482 75018 Paris), Anne Delaval (Centre Hospitalier Intercommunal Robert Ballanger, 93602 Aulnay-sous-  
483 Bois), François Martin-Barbaz (Centre Hospitalier de Niort, 79021 Niort), Bernadette Buret  
484 (Laboratoire de Biologie, Centre Hospitalier de Niort, 79021 Niort), Gianandrea Borgherini (Maladies  
485 Infectieuses, Groupe Hospitalier Sud Réunion, 97448 Réunion), Sandrine Picot (Laboratoire de  
486 Bactériologie-Parasitologie, Groupe Hospitalier Sud Réunion, 97448 Réunion), Dieudonné Bemba  
487 (Laboratoire de Microbiologie, AP-HP, Hôpital Jean Verdier, 93140 Bondy), Isabelle Poilane  
488 (Laboratoire de Microbiologie, AP-HP, Hôpital Jean Verdier, 93140 Bondy), Thanh-Van Trieu  
489 (Urgences Pédiatriques, AP-HP, Hôpital Jean Verdier, 93140 Bondy), Marie Belloy (Centre  
490 Hospitalier Intercommunal Robert Ballanger, 93602 Aulnay-sous-Bois), Martin Danis (Centre  
491 National de Référence du Paludisme, Laboratoire de Parasitologie-Mycologie, AP-HP, Hôpital La  
492 Pitié-Salpêtrière, 75013 Paris).

493 This work was supported by: Université Paris Descartes (GC, JC, JLB), Institut de Recherche pour le  
494 Développement (GC, JC, JLB), Assistance Publique des Hôpitaux de Paris (JLB), and the French  
495 malaria reference center (JLB, LM, VH, JC). Since 2002, the French malaria reference center has been

496 granted by: Institut de Veille Sanitaire, Assistance Publique des Hôpitaux de Paris, and  
497 GlaxoSmithKline.

498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555

## REFERENCES

1. **Read AF, Day T, and Huijben S.** 2011. The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy. *Proc Natl Acad Sci U S A.* **108 Suppl 2**:10871-10877.
2. **Bloland PB, Kazembe PN, Watkins WM, Doumbo OK, Nwanyanwu OC, and Ruebush TK, 2nd.** 1997. Malarone-donation programme in Africa. *Lancet.* **350**:1624-1625.
3. **Nosten F.** 2000. Prophylactic effect of Malarone against malaria: all good news? *Lancet.* **356**:1864-1865.
4. **Hoyer S, Nguon S, Kim S, Habib N, Khim N, Sum S, Christophel EM, Bjorge S, Thomson A, Kheng S, Chea N, Yok S, Top S, Ros S, Sophal U, Thompson MM, Mellor S, Arie F, Witkowski B, Yeang C, Yeung S, Duong S, Newman RD, and Menard D.** 2012. Focused Screening and Treatment (FSAT): a PCR-based strategy to detect malaria parasite carriers and contain drug resistant *P. falciparum*, Pailin, Cambodia. *PLoS One.* **7**:e45797.
5. **Nixon GL, Moss DM, Shone AE, Lalloo DG, Fisher N, O'Neill PM, Ward SA, and Biagini GA.** 2013. Antimalarial pharmacology and therapeutics of atovaquone. *J Antimicrob Chemother.* **68**:977-985.
6. **Looareesuwan S, Viravan C, Webster HK, Kyle DE, Hutchinson DB, and Canfield CJ.** 1996. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. *Am J Trop Med Hyg.* **54**:62-66.
7. **Srivastava IK, Rottenberg H, and Vaidya AB.** 1997. Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. *J Biol Chem.* **272**:3961-3966.
8. **Srivastava IK, and Vaidya AB.** 1999. A mechanism for the synergistic antimalarial action of atovaquone and proguanil. *Antimicrob Agents Chemother.* **43**:1334-1339.
9. **Peterson DS, Milhous WK, and Wellem TE.** 1990. Molecular basis of differential resistance to cycloguanil and pyrimethamine in *Plasmodium falciparum* malaria. *Proc Natl Acad Sci U S A.* **87**:3018-3022.
10. **Foote SJ, Galatis D, and Cowman AF.** 1990. Amino acids in the dihydrofolate reductase-thymidylate synthase gene of *Plasmodium falciparum* involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. *Proc Natl Acad Sci U S A.* **87**:3014-3017.
11. **Korsinczky M, Chen N, Kotecka B, Saul A, Rieckmann K, and Cheng Q.** 2000. Mutations in *Plasmodium falciparum* cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. *Antimicrob Agents Chemother.* **44**:2100-2108.
12. **Kessl JJ, Ha KH, Merritt AK, Lange BB, Hill P, Meunier B, Meshnick SR, and Trumppower BL.** 2005. Cytochrome b mutations that modify the ubiquinol-binding pocket of the cytochrome bc1 complex and confer anti-malarial drug resistance in *Saccharomyces cerevisiae*. *J Biol Chem.* **280**:17142-17148.
13. **Sirawaraporn W, Sathitkul T, Sirawaraporn R, Yuthavong Y, and Santi DV.** 1997. Antifolate-resistant mutants of *Plasmodium falciparum* dihydrofolate reductase. *Proc Natl Acad Sci U S A.* **94**:1124-1129.
14. **Basco LK, and Ringwald P.** 2000. Molecular epidemiology of malaria in Yaounde, Cameroon. VI. Sequence variations in the *Plasmodium falciparum* dihydrofolate reductase-thymidylate synthase gene and in vitro resistance to pyrimethamine and cycloguanil. *Am J Trop Med Hyg.* **62**:271-276.
15. **Naidoo I, and Roper C.** 2013. Mapping 'partially resistant', 'fully resistant', and 'super resistant' malaria. *Trends Parasitol.*
16. **Musset L, Pradines B, Parzy D, Durand R, Bigot P, and Le Bras J.** 2006. Apparent absence of atovaquone/proguanil resistance in 477 *Plasmodium falciparum* isolates from untreated French travellers. *J Antimicrob Chemother.* **57**:110-115.
17. **Ekala MT, Khim N, Legrand E, Randrianarivojosia M, Jambou R, Fandeur T, Menard D, Assi SB, Henry MC, Rogier C, Bouchier C, and Mercereau-Puijalon O.** 2007. Sequence analysis of *Plasmodium falciparum* cytochrome b in multiple geographic sites. *Malar J.* **6**:164.
18. **Tanabe K, Jombart T, Horibe S, Palacpac NM, Honma H, Tachibana S, Nakamura M, Horii T, Kishino H, and Mita T.** 2013. *Plasmodium falciparum* mitochondrial genetic diversity exhibits isolation-by-distance patterns supporting a sub-Saharan African origin. *Mitochondrion.* **13**:630-636.
19. **Sutherland CJ, Laundry M, Price N, Burke M, Fivelman QL, Pasvol G, Klein JL, and Chiodini PL.** 2008. Mutations in the *Plasmodium falciparum* cytochrome b gene are associated with delayed parasite recrudescence in malaria patients treated with atovaquone-proguanil. *Malar J.* **7**:240.
20. **Schwartz E, Bujanover S, and Kain KC.** 2003. Genetic confirmation of atovaquone-proguanil-resistant *Plasmodium falciparum* malaria acquired by a nonimmune traveler to East Africa. *Clin Infect Dis.* **37**:450-451.

- 556 21. **Musset L, Bouchaud O, Matheron S, Massias L, and Le Bras J.** 2006. Clinical atovaquone-  
557 proguanil resistance of *Plasmodium falciparum* associated with cytochrome b codon 268 mutations.  
558 *Microbes Infect.* **8**:2599-2604.
- 559 22. **Musset L, Le Bras J, and Clain J.** 2007. Parallel evolution of adaptive mutations in *Plasmodium*  
560 *falciparum* mitochondrial DNA during atovaquone-proguanil treatment. *Mol Biol Evol.* **24**:1582-1585.
- 561 23. **Srivastava IK, Morrisey JM, Darrouzet E, Daldal F, and Vaidya AB.** 1999. Resistance mutations  
562 reveal the atovaquone-binding domain of cytochrome b in malaria parasites. *Mol Microbiol.* **33**:704-  
563 711.
- 564 24. **Preiser PR, Wilson RJ, Moore PW, McCready S, Hajibagheri MA, Blight KJ, Strath M, and**  
565 **Williamson DH.** 1996. Recombination associated with replication of malarial mitochondrial DNA.  
566 *EMBO J.* **15**:684-693.
- 567 25. **Birky CW, Jr.** 1994. Relaxed and stringent genomes: why cytoplasmic genes don't obey Mendel's  
568 laws. *J Hered.* **85**:355-365.
- 569 26. **Hastings IM.** 2004. The origins of antimalarial drug resistance. *Trends Parasitol.* **20**:512-518.
- 570 27. **van Dooren GG, Marti M, Tonkin CJ, Stimmler LM, Cowman AF, and McFadden GI.** 2005.  
571 Development of the endoplasmic reticulum, mitochondrion and apicoplast during the asexual life cycle  
572 of *Plasmodium falciparum*. *Mol Microbiol.* **57**:405-419.
- 573 28. **Coller HA, Khrapko K, Bodyak ND, Nekhaeva E, Herrero-Jimenez P, and Thilly WG.** 2001. High  
574 frequency of homoplasmic mitochondrial DNA mutations in human tumors can be explained without  
575 selection. *Nat Genet.* **28**:147-150.
- 576 29. **Slomianny C, and Prensier G.** 1986. Application of the serial sectioning and tridimensional  
577 reconstruction techniques to the morphological study of the *Plasmodium falciparum* mitochondrion. *J*  
578 *Parasitol.* **72**:595-598.
- 579 30. **Peters JM, Chen N, Gatton M, Korsinczky M, Fowler EV, Manzetti S, Saul A, and Cheng Q.**  
580 2002. Mutations in cytochrome b resulting in atovaquone resistance are associated with loss of fitness  
581 in *Plasmodium falciparum*. *Antimicrob Agents Chemother.* **46**:2435-2441.
- 582 31. **Fisher N, Abd Majid R, Antoine T, Al-Helal M, Warman AJ, Johnson DJ, Lawrenson AS,**  
583 **Ranson H, O'Neill PM, Ward SA, and Biagini GA.** 2012. Cytochrome b mutation Y268S conferring  
584 atovaquone resistance phenotype in malaria parasite results in reduced parasite bc1 catalytic turnover  
585 and protein expression. *J Biol Chem.* **287**:9731-9741.
- 586 32. **Lynch M, Sung W, Morris K, Coffey N, Landry CR, Dopman EB, Dickinson WJ, Okamoto K,**  
587 **Kulkarni S, Hartl DL, and Thomas WK.** 2008. A genome-wide view of the spectrum of spontaneous  
588 mutations in yeast. *Proc Natl Acad Sci U S A.* **105**:9272-9277.
- 589 33. **Haag-Liautard C, Coffey N, Houle D, Lynch M, Charlesworth B, and Keightley PD.** 2008. Direct  
590 estimation of the mitochondrial DNA mutation rate in *Drosophila melanogaster*. *PLoS Biol.* **6**:e204.
- 591 34. **Saxer G, Havlak P, Fox SA, Quance MA, Gupta S, Fofanov Y, Strassmann JE, and Queller DC.**  
592 2012. Whole genome sequencing of mutation accumulation lines reveals a low mutation rate in the  
593 social amoeba *Dictyostelium discoideum*. *PLoS One.* **7**:e46759.
- 594 35. **Sung W, Tucker AE, Doak TG, Choi E, Thomas WK, and Lynch M.** 2012. Extraordinary genome  
595 stability in the ciliate *Paramecium tetraurelia*. *Proc Natl Acad Sci U S A.* **109**:19339-19344.
- 596 36. **Bopp SE, Manary MJ, Bright AT, Johnston GL, Dharia NV, Luna FL, McCormack S, Plouffe D,**  
597 **McNamara CW, Walker JR, Fidock DA, Denchi EL, and Winzeler EA.** 2013. Mitotic evolution of  
598 *Plasmodium falciparum* shows a stable core genome but recombination in antigen families. *PLoS*  
599 *Genet.* **9**:e1003293.
- 600 37. **Roestenberg M, O'Hara GA, Duncan CJ, Epstein JE, Edwards NJ, Scholzen A, van der Ven AJ,**  
601 **Hermesen CC, Hill AV, and Sauerwein RW.** 2012. Comparison of clinical and parasitological data  
602 from controlled human malaria infection trials. *PLoS One.* **7**:e38434.
- 603 38. **Briand V, Bouchaud O, Tourret J, Behr C, Abgrall S, Ralaimazava P, Le Bras J, and Fontanet A.**  
604 2007. Hospitalization criteria in imported falciparum malaria. *J Travel Med.* **14**:306-311.
- 605 39. **Maiga-Ascofare O, Le Bras J, Mazmouz R, Renard E, Falcao S, Broussier E, Bustos D,**  
606 **Randrianarivelosia M, Omar SA, Aubouy A, Lepere JF, Jean-Francois V, Djimde AA, and**  
607 **Clain J.** 2010. Adaptive differentiation of *Plasmodium falciparum* populations inferred from single-  
608 nucleotide polymorphisms (SNPs) conferring drug resistance and from neutral SNPs. *J Infect Dis.*  
609 **202**:1095-1103.
- 610 40. **White NJ.** 2002. The assessment of antimalarial drug efficacy. *Trends Parasitol.* **18**:458-464.
- 611 41. **White NJ.** 1997. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo.  
612 *Antimicrob Agents Chemother.* **41**:1413-1422.
- 613 42. **White NJ.** 2013. Pharmacokinetic and pharmacodynamic considerations in antimalarial dose  
614 optimization. *Antimicrob Agents Chemother.* **57**:5792-5807.

- 615 43. **Chiodini PL, Conlon CP, Hutchinson DB, Farquhar JA, Hall AP, Peto TE, Birley H, and Warrell**  
616 **DA.** 1995. Evaluation of atovaquone in the treatment of patients with uncomplicated Plasmodium  
617 falciparum malaria. *J Antimicrob Chemother.* **36**:1073-1078.
- 618 44. **Kuhn S, Gill MJ, and Kain KC.** 2005. Emergence of atovaquone-proguanil resistance during  
619 treatment of Plasmodium falciparum malaria acquired by a non-immune north American traveller to  
620 west Africa. *Am J Trop Med Hyg.* **72**:407-409.
- 621 45. **Savini H, Bogreau H, Bertaux L, Bouchiba H, Kraemer P, Parzy D, Garnotel E, Rogier C, Simon**  
622 **F, and Pradines B.** 2008. First case of emergence of atovaquone-proguanil resistance in Plasmodium  
623 falciparum during treatment in a traveler in Comoros. *Antimicrob Agents Chemother.* **52**:2283-2284.
- 624 46. **Schmitt MW, Kennedy SR, Salk JJ, Fox EJ, Hiatt JB, and Loeb LA.** 2012. Detection of ultra-rare  
625 mutations by next-generation sequencing. *Proc Natl Acad Sci U S A.* **109**:14508-14513.
- 626 47. **Kennedy SR, Salk JJ, Schmitt MW, and Loeb LA.** 2013. Ultra-sensitive sequencing reveals an age-  
627 related increase in somatic mitochondrial mutations that are inconsistent with oxidative damage. *PLoS*  
628 *Genet.* **9**:e1003794.
- 629 48. **Ford CB, Shah RR, Maeda MK, Gagneux S, Murray MB, Cohen T, Johnston JC, Gardy J,**  
630 **Lipsitch M, and Fortune SM.** 2013. Mycobacterium tuberculosis mutation rate estimates from  
631 different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. *Nat*  
632 *Genet.* **45**:784-790.
- 633 49. **Colijn C, Cohen T, Ganesh A, and Murray M.** 2011. Spontaneous emergence of multiple drug  
634 resistance in tuberculosis before and during therapy. *PLoS One.* **6**:e18327.
- 635 50. **Pennings PS.** 2012. Standing genetic variation and the evolution of drug resistance in HIV. *PLoS*  
636 *Comput Biol.* **8**:e1002527.
- 637 51. **White NJ, and Pongtavornpinyo W.** 2003. The de novo selection of drug-resistant malaria parasites.  
638 *Proc Biol Sci.* **270**:545-554.
- 639 52. **McCarthy JS, Sekuloski S, Griffin PM, Elliott S, Douglas N, Peatey C, Rockett R, O'Rourke P,**  
640 **Marquart L, Hermsen C, Duparc S, Mohrle J, Trenholme KR, and Humberstone AJ.** 2011. A  
641 pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers  
642 for testing efficacy of new antimalarial drugs. *PLoS One.* **6**:e21914.
- 643 53. **Fry M, and Pudney M.** 1992. Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4'-  
644 chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). *Biochem Pharmacol.* **43**:1545-  
645 1553.
- 646 54. **Roepe PD.** 2014. To kill or not to kill, that is the question: cytotoxic antimalarial drug resistance.  
647 *Trends Parasitol.* **30**:130-135.
- 648 55. **Hussein Z, Eaves CJ, Hutchinson DB, and Canfield CJ.** 1996. Population pharmacokinetics of  
649 proguanil in patients with acute P. falciparum malaria after combined therapy with atovaquone. *Br J*  
650 *Clin Pharmacol.* **42**:589-597.
- 651 56. **Hussein Z, Eaves J, Hutchinson DB, and Canfield CJ.** 1997. Population pharmacokinetics of  
652 atovaquone in patients with acute malaria caused by Plasmodium falciparum. *Clin Pharmacol Ther.*  
653 **61**:518-530.
- 654 57. **White NJ, Pongtavornpinyo W, Maude RJ, Saralamba S, Aguas R, Stepniewska K, Lee SJ,**  
655 **Dondorp AM, White LJ, and Day NP.** 2009. Hyperparasitaemia and low dosing are an important  
656 source of anti-malarial drug resistance. *Malar J.* **8**:253.
- 657 58. **Fivelman QL, Butcher GA, Adagu IS, Warhurst DC, and Pasvol G.** 2002. Malarone treatment  
658 failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria.  
659 *Malar J.* **1**:1.
- 660 59. **Perry TL, Pandey P, Grant JM, and Kain KC.** 2009. Severe atovaquone-resistant Plasmodium  
661 falciparum malaria in a Canadian traveller returned from the Indian subcontinent. *Open Med.* **3**:e10-16.
- 662 60. **Rose GW, Suh KN, Kain KC, Le Saux N, and McCarthy AE.** 2008. Atovaquone-proguanil  
663 resistance in imported falciparum malaria in a young child. *Pediatr Infect Dis J.* **27**:567-569.
- 664 61. **Roberts CH, Armstrong M, Zatyka E, Boadi S, Warren S, Chiodini PL, Sutherland CJ, and**  
665 **Doherty T.** 2013. Gametocyte carriage in Plasmodium falciparum-infected travellers. *Malar J.* **12**:31.
- 666 62. **Rathod PK, McErlean T, and Lee PC.** 1997. Variations in frequencies of drug resistance in  
667 Plasmodium falciparum. *Proc Natl Acad Sci U S A.* **94**:9389-9393.
- 668 63. **Pongtavornpinyo W, Hastings IM, Dondorp A, White LJ, Maude RJ, Saralamba S, Day NP,**  
669 **White NJ, and Boni MF.** 2009. Probability of emergence of antimalarial resistance in different stages  
670 of the parasite life cycle. *Evol Appl.* **2**:52-61.
- 671 64. **Johnston GL, Smith DL, and Fidock DA.** 2013. Malaria's missing number: calculating the human  
672 component of R0 by a within-host mechanistic model of Plasmodium falciparum infection and  
673 transmission. *PLoS Comput Biol.* **9**:e1003025.

- 674 65. **Dong CK, Uргаonkar S, Cortese JF, Gamo FJ, Garcia-Bustos JF, Lafuente MJ, Patel V, Ross L,**  
675 **Coleman BI, Derbyshire ER, Clish CB, Serrano AE, Cromwell M, Barker RH, Jr., Dvorin JD,**  
676 **Duraisingh MT, Wirth DF, Clardy J, and Mazitschek R.** 2011. Identification and validation of  
677 tetracyclic benzothiazepines as *Plasmodium falciparum* cytochrome bcl inhibitors. *Chem Biol.*  
678 **18:1602-1610.**
- 679 66. **Nam TG, McNamara CW, Bopp S, Dharia NV, Meister S, Bonamy GM, Plouffe DM, Kato N,**  
680 **McCormack S, Bursulaya B, Ke H, Vaidya AB, Schultz PG, and Winzeler EA.** 2011. A chemical  
681 genomic analysis of decoquinatone, a *Plasmodium falciparum* cytochrome b inhibitor. *ACS Chem Biol.*  
682 **6:1214-1222.**
- 683 67. **Biagini GA, Fisher N, Shone AE, Mubarak MA, Srivastava A, Hill A, Antoine T, Warman AJ,**  
684 **Davies J, Pidathala C, Amewu RK, Leung SC, Sharma R, Gibbons P, Hong DW, Pacorel B,**  
685 **Lawrenson AS, Charoensutthivarakul S, Taylor L, Berger O, Mbekeani A, Stocks PA, Nixon GL,**  
686 **Chadwick J, Hemingway J, Delves MJ, Sinden RE, Zeeman AM, Kocken CH, Berry NG, O'Neill**  
687 **PM, and Ward SA.** 2012. Generation of quinolone antimalarials targeting the *Plasmodium falciparum*  
688 mitochondrial respiratory chain for the treatment and prophylaxis of malaria. *Proc Natl Acad Sci U S A.*  
689 **109:8298-8303.**
- 690 68. **Nilsen A, LaCrue AN, White KL, Forquer IP, Cross RM, Marfurt J, Mather MW, Delves MJ,**  
691 **Shackleford DM, Saenz FE, Morrisey JM, Steuten J, Mutka T, Li Y, Wirjanata G, Ryan E, Duffy**  
692 **S, Kelly JX, Sebayang BF, Zeeman AM, Noviyanti R, Sinden RE, Kocken CH, Price RN, Avery**  
693 **VM, Angulo-Barturen I, Jimenez-Diaz MB, Ferrer S, Herreros E, Sanz LM, Gamo FJ, Bathurst**  
694 **I, Burrows JN, Siegl P, Guy RK, Winter RW, Vaidya AB, Charman SA, Kyle DE, Manetsch R,**  
695 **and Riscoe MK.** 2013. Quinolone-3-diarylethers: a new class of antimalarial drug. *Sci Transl Med.*  
696 **5:177ra137.**
- 697 69. **Backer JS, and Birky CW, Jr.** 1985. The origin of mutant cells: mechanisms by which  
698 *Saccharomyces cerevisiae* produces cells homoplasmic for new mitochondrial mutations. *Curr Genet.*  
699 **9:627-640.**
- 700 70. **Huijben S, Bell AS, Sim DG, Tomasello D, Mideo N, Day T, and Read AF.** 2013. Aggressive  
701 Chemotherapy and the Selection of Drug Resistant Pathogens. *PLoS Pathog.* **9:e1003578.**
- 702 71. **van Vugt M, Leonardi E, Phaipun L, Slight T, Thway KL, McGready R, Brockman A, Villegas L,**  
703 **Looareesuwan S, White NJ, and Nosten F.** 2002. Treatment of uncomplicated multidrug-resistant  
704 *falciparum* malaria with artesunate-atovaquone-proguanil. *Clin Infect Dis.* **35:1498-1504.**
- 705 72. **McGready R, Keo NK, Villegas L, White NJ, Looareesuwan S, and Nosten F.** 2003. Artesunate-  
706 atovaquone-proguanil rescue treatment of multidrug-resistant *Plasmodium falciparum* malaria in  
707 pregnancy: a preliminary report. *Trans R Soc Trop Med Hyg.* **97:592-594.**
- 708 73. **McGready R, Ashley EA, Moo E, Cho T, Barends M, Hutagalung R, Looareesuwan S, White NJ,**  
709 **and Nosten F.** 2005. A randomized comparison of artesunate-atovaquone-proguanil versus quinine in  
710 treatment for uncomplicated *falciparum* malaria during pregnancy. *J Infect Dis.* **192:846-853.**  
711

712 **Figure legends**

713

714 **Figure 1. Dynamics and loads of mtDNA mutant parasites per human host.** Data are from  
715 20,000 simulations, with one simulation representing one human infection. **A**, triangles  
716 represent homoplasmic-mutant parasites and circles represent all-mutants (either  
717 heteroplasmic or homoplasmic-mutants); plain and dashed lines represent the median and the  
718 99.5<sup>th</sup> percentile, respectively. **B**, triangle and circle symbols represent homoplasmic-mutant  
719 and all-mutants parasites, respectively. **C** and **D**, data are from simulations stopped at the 6<sup>th</sup>  
720 erythrocytic 48h-cycle following parasite delivery from the liver (corresponding to a mean  
721 total parasite load per host of  $1.5 \times 10^{11}$ ). The load of mutant parasites per host is shown,  
722 according to the number of mtDNA mutant copies per parasite. **C**, each line (either plain or  
723 dashed) represents one simulated infected host randomly chosen among 20,000 simulations.  
724 Five simulations are shown. **D**, box-plots show the median and inter-quartile range (IQR), and  
725 the bottom and top whiskers show the lowest data still within 1.5xIQR of the lower quartile  
726 and the highest data still within 1.5xIQR of the upper quartile, respectively. Outlier values are  
727 shown as dots. There is no mutation cost, the mtDNA copy number is 20, and the mutation  
728 rate is  $10^{-10}$ /nucleotide/replication in all the simulations presented here.

729

730 **Figure 2. Load of mtDNA mutant parasites per human host according to different**  
731 **parameters.** Data are from 20,000 simulations, with one simulation representing one infected  
732 host. **A, C, E and G:** refer to all-mutant parasites, *id est* having at least one of their  $n$  mtDNA  
733 copies being mutated. **B, D, F and H:** refer to homoplasmic-mutant, *id est* parasites having all  
734 of their  $n$  mtDNA copies being mutated. **E and F**, at the 5<sup>th</sup>, 6<sup>th</sup> and 7<sup>th</sup> erythrocytic 48hr-  
735 cycles, there is a mean number of  $1.2 \times 10^{10}$ ,  $1.5 \times 10^{11}$ , and  $1.8 \times 10^{12}$  parasites per host in our  
736 simulations, respectively. Except if differently stated, mutation rate is  $10^{-10}$   
737 /nucleotide/replication, there is no resistance mutation cost (neutral), the mtDNA copy  
738 number is 20, and the parasite load per host is  $1.5 \times 10^{11}$  (corresponding to the 6<sup>th</sup> erythrocytic  
739 48hr-cycles following parasite delivery from the liver). neu: neutral, rec: recessive, dom:  
740 dominant. Box-plots show the median and inter-quartile range (IQR), and the bottom and top  
741 whiskers show the lowest data still within 1.5xIQR of the lower quartile and the highest data  
742 still within 1.5xIQR of the upper quartile, respectively. Outlier values are shown as dots.

743

744 **Figure 3. Proportion of infections carrying mutant parasites.** Data are from 20,000  
745 simulations, with one simulation representing one human infected host. **A:** y-axis scale ranges

746 from 0 to 100; **B**: same data as in **A** but y-axis scale ranges from 0 to 2.5. Black, red, and blue  
747 lines represent infections after 5, 6, and 7 erythrocytic 48hr-cycles, respectively, following  
748 parasite release from the liver. This corresponds to a mean of  $1.2 \times 10^{10}$ ,  $1.5 \times 10^{11}$ , and  $1.8 \times 10^{12}$   
749 parasites per host, respectively. The mtDNA copy number is 20, the mutation rate is  $10^{-10}$   
750 /nucleotide/replication, and the mutation cost is recessive in the simulations presented here.  
751  $\geq 1/20$  refers to parasites having at least one of their 20 mtDNA copies being mutated (*id est*  
752 all-mutant);  $\geq 10/20$  refers to parasites having at least 10 of their 20 mtDNA copies being  
753 mutated; and  $20/20$  refers to parasites having all of their 20 mtDNA copies being mutated (*id*  
754 *est* homoplasmic-mutant).  
755  
756



757 **Table 1. Patients reported in the study.**

Patient*	Sex	Age (year)	Weight (kg)	Isolate (day) <sup>†</sup>	Drug <sup>‡</sup>	Parasitemia (%)	Plasma drug (μM) <sup>  ,**</sup>				Parasite genetics <sup>**</sup>						
							Ato	Pro	Cyc	Others	<i>cytb</i>	<i>dhfr</i>	Microsatellites <sup>§§</sup>				
											TAA 81	TAA 87	PfPk2	Ara2	TAA 60		
P1	M	24	55	d0	AP	<0.005	-	-	-	-	Y	-	179	93	-	-	94
				d25/d0	AP	0.1	-	-	-	-	S	IRN	179	93	169	103	94
				d26/d1		-	1.20	0.48	0.18	neg	-	-	-	-	-	-	-
P2	M	12	40	d45/d20	QN	0.4	-	-	-	-	S	IRN	179	93	169	103	94
				d0	AP	2.9	neg	neg	neg	neg	Y	IRN	173	84	172	106	82
				d8		neg	-	-	-	-	-	-	-	-	-	-	-
P3	M	9	53	d35/d0	AP	0.5	neg	neg	neg	neg	S	IRN	173	84	172	106	82
				d65/d30	MFQ	<0.1	-	-	-	-	S	IRN	173	84	172	106	82
				d0	AP	6.6	neg	neg	neg	neg	Y	IRN	182	-	172	103	95
P4	F	59	64	d7		neg	4.12	0.02	neg	neg	Y	IRN	182	-	172	103	-
				d29/d0	AP	12.5	-	-	-	-	C	IRN	182	-	172	103	95
				d32/d3		0.01	-	-	-	-	C	-	-	-	172	103	95
P5	F	14	52	d49/d20	QN	3.5	0.39	neg	neg	neg	C	IRN	182	-	172	103	95
				d0	AP	1	-	-	-	-	-	-	-	-	-	-	-
				d12		neg	2.39	neg	neg	neg	Y	-	-	-	-	-	-
P6	M	0.5	8	d24/d0	AP	1	-	-	-	-	C	IRN	179	81	163	109	95
				d32/d8		neg	7.98	0.04	neg	neg	C	-	-	81	163	-	95
				d46/d22	QN	0.2	2.54	neg	neg	neg	C	IRN	179	81	163	109	94
P7	M	58	70	d0	AP	0.3	-	-	-	-	Y	IRN	179	84	169,172	103	79
				d10		neg	-	-	-	-	-	-	-	-	-	-	-
				d23/d0	AP	0.1	-	-	-	-	S	IRN	-	-	-	-	-
P6	M	0.5	8	d31/d8		<0.1 <sup>§</sup>	4.10	neg	neg	-	S	IRN	-	-	-	-	-
				d39/d16	MFQ	0.25	-	-	-	-	S	IRN	179	84	172	103	79
				d0	AP	4	-	-	-	-	-	-	-	-	-	-	-
P6	M	0.5	8	d3		<0.1	-	-	-	-	Y	IRN	179	96	190	112	91
				d19/d0	AP	6	-	-	-	-	Y+C	IRN	179	96	190	112	91
				d22/d3	MFQ	0.2	-	-	-	-	-	-	-	-	-	-	-
P7	M	58	70	d0	AP	2	neg	neg	neg	neg	Y	IRN	164	93	166	127	91
				d22		neg	-	-	-	-	-	-	-	-	-	-	-
				d27/d0	AP	1.5	0.10	neg	neg	neg	C+S <sup>‡</sup>	IRN	164	93	166	127	91
				d32/d5	QN	0.0003 <sup>†</sup>	3.62	0.09	0.04	neg	C+S	IRN	164	93	166	127	91

758 \*, patients P1 to P7 were infected in The Union of the Comoros, Mali, Senegal, Gabon, Ivory Coast, The Union of the Comoros, and Togo,  
759 respectively. All are of African ethnicity except P7 who is Caucasian; patient P5 was already reported in (11); additional informations and full  
760 case report are provided here.

761 †, d0 corresponds to the day of diagnosis and treatment initiation.

762 ‡, drug used for treatment; AP, atovaquone-proguanil; MFQ, mefloquine; QN, quinine.  
763 §, few trophozoites detected on the thin and thick smears.  
764 ¶, calculated peripheral parasitemia, based on 14 parasites / $\mu$ L detected on the thick smear and a measured erythrocyte concentration of 3.7 T/L.  
765 □, Ato, atovaquone; Pro, proguanil; Cyc, cycloguanil; Others: monodesethyl-chloroquine, chloroquine, doxycycline, sulfadoxine,  
766 pyrimethamine, mefloquine, carboxy-mefloquine, amodiaquine, monodesethyl-amodiaquine, desbutyl-halofantrine, lumefantrine, dihydro-  
767 artemisinin; the lower limit of quantification was 5 $\mu$ g/L, which corresponds to 0.014 $\mu$ M, 0.020 $\mu$ M, and 0.020 $\mu$ M, for atovaquone, cycloguanil  
768 and proguanil, respectively.  
769 \*\*, "neg" means not detected ; "-" means not done.  
770 ††, *cytb*: codon 268 was analyzed, wild type is Tyrosine (Y) and mutants are Serine (S) and Cysteine (C); the mutations *cytb* Y268S and Y268C  
771 confer resistance to atovaquone; *dhfr*: the triple *dhfr* mutation N51I+C59R+S108N confers resistance to cycloguanil.  
772 ‡‡, the presence of the 2 mutations Y268S and Y268C within the same isolate was confirmed by cloning the PCR product and subsequent  
773 sequencing of multiple clones (supplementary figure 1).  
774 §§, allele size (in base pair) of PCR products are reported.  
775

776 **Table 2.** Time required to clear the *de novo* mtDNA mutant parasites emerging from primary  
 777 infections.  
 778

Total parasite load per patient	Fraction of mutated mtDNA copies <sup>‡</sup>	Mutant parasite load per patient*			Mutant clearance time (days) <sup>†</sup>
		Median	Min.	Max.	
1.8x10 <sup>12</sup>	20/20	6	0	176,395	6.2
	≥10/20	651	99	1,480,258	7.2
	≥1/20	11,132	8,418	3,049,318	7.6
1.5x10 <sup>11</sup>	20/20	0	0	6,157	4.5
	≥10/20	25	0	79,843	5.8
	≥1/20	825	443	210,890	6.2
1.2x10 <sup>10</sup>	20/20	0	0	448	3.1
	≥10/20	0	0	6,960	4.5
	≥1/20	58	17	18,352	5.0


779 <sup>‡</sup>, ≥1/20 refers to parasites having at least one of their 20 mtDNA copies being mutated (*id est* all-mutant);  
 780

781 ≥10/20 refers to parasites having at least 10 of their 20 mtDNA copies being mutated; and 20/20 refers to  
 782 parasites having all of their 20 mtDNA copies being mutated (*id est* homoplasmic-mutant)


783 \*, Data are from 20,000 simulations performed with the following parameters: recessive mutation cost, mtDNA  
 784 copy number = 20, and mutation rate = 10<sup>-10</sup>/nucleotidic site/replication.

785 <sup>†</sup>, Assuming a constant parasite reduction ratio for AP-resistant parasites of 50. Maximum (Max.) mutant  
 786 parasite loads are used for the estimation.


A




B













C



D





**A****B**

## Supplementary materials

### 1) The mathematical description of the model:

The following sections describe the appearance of mtDNA mutations and their propagation to daughter mtDNA copies and parasites along one erythrocytic 48hr-cycle. This erythrocytic 48hr-cycle was repeated up to 7 times in a row to simulate the parasite blood stage growth during a *P. falciparum* malaria primary infection in a non-immune patient. During one intra-erythrocytic 48h-cycle, each *P. falciparum* parasite undergoes 5 consecutive endo-mitosis (that occur within a single parasite), resulting theoretically in the production of  $2^5 = 32$  daughter parasites per initial parasite.

#### Spontaneous mutation

At the mtDNA replication  $d$ , each wild type parasite has a probability of spontaneous mtDNA mutation  $p = 1 - (1 - \mu)^n$ , where  $\mu$  is the mutation rate and  $n$  is the mtDNA copy number.

The probability of 2 or more spontaneous mutations in the same parasite as well as the probability of a spontaneous mutation among the parasite populations  $P_{1,d}, \dots, P_{n,d}$  were assumed to be negligible (where  $P_{i,d}$  is the population of mutant parasites having  $i$  mtDNA copies being mutated).

At each mtDNA replication  $d$ , the number of wild type parasites which mutate spontaneously has a binomial distribution  $\text{Bin}(N_{0,d}, p)$ , where  $N_{0,d}$  is the number of wild type parasite at the division  $d$ .

#### Duplication of the mtDNA

The  $n$  mtDNA template copies to be duplicated during one mtDNA replication are randomly drawn with replacement among the  $n$  initial mtDNA copies. Thus, for a parasite with  $k$  mutated mtDNA copies ( $k$  in  $\{0, \dots, n\}$ ), the number  $M$  of mutated mtDNA copies that are duplicated during one division has a binomial distribution  $\text{Bin}(n, k/n)$ , with the corresponding probability  $p_{\text{repl}_i} = P(M=i)$ .

The  $N_{k,d}$  parasites with  $k$  mtDNA mutated copies at replication  $d$  generate potentially (at most)  $n+1$  distinct mutant parasite populations having a duplicated mtDNA genome: the population  $P_{k,d,0}$  for which 0 mutated mtDNA copy have been duplicated, the population  $P_{k,d,1}$  for which 1 mutated mtDNA copy have been duplicated, ..., the population  $P_{k,d,n}$  for which  $n$  mutated mtDNA copies have been duplicated.

All the parasites of a population  $P_{k,d,x}$  have  $k+x$  mutated mtDNA copies among  $2n$  ( $x$  in  $\{0, \dots, n\}$ ).

$(N_{k,d,0}, N_{k,d,1}, \dots, N_{k,d,n})$  has a multinomial distribution  $M(N_{k,d}, p_{\text{repl}_0}, p_{\text{repl}_1}, \dots, p_{\text{repl}_n})$ , where  $N_{k,d,x}$  is

the size of a parasite population  $P_{k,d,x}$  and  $\sum_{x=0}^n N_{k,d,x} = N_{k,d}$

#### Partitioning of the mtDNA copies among 2 daughter separated mitochondrial units

The mtDNA duplication for all parasite populations  $P_{1,d}, \dots, P_{n,d}$  at the replication  $d$  generates potentially  $2n+1$  parasite populations  $P'_{k,d}$  ( $k$  in  $\{0, \dots, 2n\}$ ), where  $k$  is the number of mutated mtDNA copies among  $2n$ . The segregation of  $n$  mtDNA copies is modelled as the random draw without replacement of  $n$  mtDNA copies among  $2n$ , generating 2 separated daughter mtDNA unit

having each  $n$  mtDNA copies. The daughter mtDNA units being separated, they were further considered as independent daughter “transient” parasites for convenience.

**First case:  $k < n$**

Each parasite of a population  $P'_{k,d}$  generates one of the  $k+1$  different couples  $C^1_j$  of daughter parasites ( $j$  in  $\{0, \dots, k\}$ ), with a probability  $P_{C^1_j}$  according to an hypergeometric distribution  $H(2n, k, n)$ . A couple  $C^1_j$  contains a daughter parasite with  $j$  mutated mtDNA copies among  $n$  and the other with  $k-j$  mutated mtDNA copies among  $n$ .

The  $N'_{k,d}$  parasites of the population  $P'_{k,d}$  generate  $N'_{k,d,j}$  couples  $C^1_j$ , and  $\sum_{j=0}^k N'_{k,d,j} = N'_{k,d}$   
 $(N'_{k,d,0}, N'_{k,d,1}, \dots, N'_{k,d,k})$  has a multinomial distribution  $M(N'_{k,d}, P_{C^1_0}, P_{C^1_1}, \dots, P_{C^1_k})$ .

**Second case:  $k \geq n$**

Each parasite of a population  $P'_{k,d}$  generates one of the  $k+1$  different couples  $C^2_j$  of daughter parasites ( $j$  in  $\{0, \dots, k\}$ ), with a probability  $P_{C^2_j}$  according to an hypergeometric distribution  $H(2n, k, n)$ . A couple  $C^2_j$  contains one daughter parasite with  $j$  wild type mtDNA copies among  $n$  and the other with  $k-j$  wild type mtDNA copies among  $n$ .

The  $N'_{k,d}$  parasites of the population  $P'_{k,d}$  generate  $N'_{k,d,j}$  couples  $C^2_j$  and  $\sum_{j=0}^k N'_{k,d,j} = N'_{k,d}$   
 $(N'_{k,d,0}, N'_{k,d,1}, \dots, N'_{k,d,k})$  has a multinomial distribution  $M(N'_{k,d}, P_{C^2_0}, P_{C^2_1}, \dots, P_{C^2_k})$

After 5 consecutive cycles of this duplication-partitioning process (which mimic the 5 consecutive endo-mitosis that occur within a single parasite during its erythrocytic 48h-cycle), the number of survival parasites from each genotypically distinct parasite population (wild-type, heteroplasmic, homoplasmic-mutant) is drawn in a binomial distribution  $\text{Bin}(N_i, p_{\text{surv}})$ , where  $N_i$  is the number of parasite of the parasite population with  $i$  mutated copies (from 0 to  $n$ ) and  $p_{\text{surv}}$  is the survival probability of each parasite population (varying according to the number of mutated mtDNA copies per parasite, as explained in the main section). Each surviving parasite will initiate a new erythrocytic 48hr-cycle.

**2) Supplementary results & discussion**

**Case reports:**

**Patient 1** is a 24-year-old African male (weight: 55 kg) living in La Réunion Island, France. He visited family during three months in an urban area in The Union of the Comoros in 2008-09. He declared not taking any antimalarial chemoprophylaxis. Thirteen days after returning home he started experiencing fever and vomiting. A peripheral blood film examination performed at the hospital



laboratory showed *P. falciparum* (parasitemia: <0.005%). A standard 3-day AP treatment (1,000 mg of atovaquone and 400 mg of proguanil, once a day for 3 days) was prescribed but was incompletely taken: the patient received the first dose of AP at the hospital and went home. He took the second dose at home while vomiting, and did not take the third dose because he felt better. At day-25 the patient presented to the hospital and blood smears showed *P. falciparum* parasites (parasitemia: 0.1%). The patient was admitted to hospital for 4 days, and with the history of vomiting during the treatment of the first malaria episode, the recrudescence infection was treated again with a standard 3-day AP treatment. No vomiting was reported during this treatment period. At day-45 (day-20 after the treatment of the recrudescence infection) the patient presented to the hospital with fever (symptoms have started 4 days earlier) and blood smears showed *P. falciparum* parasites (parasitemia: 0.4%). He was admitted to the hospital (4-day stay) and the second recrudescence infection was successfully treated with quinine for seven days. Parasite DNA was extracted from day-0, day-25, day-26 and day-45 isolates (either directly from blood samples or from blood smears or plasma).

**Patient 2** is a 12-year-old male weighing 40 kg. He was born in France to African parents living in France. He travelled during 5 weeks to Mali during summer 2010. He declared using chloroquine as antimalarial chemoprophylaxis but stopped prematurely. Eight days after returning to France he started experiencing fever without vomiting. A peripheral blood film examination showed *P. falciparum* parasites (parasitemia: 2.9%). The patient was admitted to the hospital for 2 days and treated with 750 mg of atovaquone and 300 mg of proguanil, once a day for 3 days. Vomiting occurred 1h20min after intake of the first dose. At the day-8 follow-up, no parasites were detected. At day-35, the patient presented to the hospital with fever that started 4 days earlier, headache and body aches ; *P. falciparum* trophozoites were detected on blood film (parasitemia: 0.5%). The patient was treated with 1,000 mg of atovaquone and 400 mg of proguanil, once a day for 5 days instead of 3 days. The patient was not admitted to hospital and the treatment was not supervised. At day-65 (day-30 after the treatment of the recrudescence infection), the patient had fever and trophozoites and gametocytes were detected (parasitemia: <0.1%). The second recrudescence infection was successfully treated with oral mefloquine. Parasite DNA was extracted from day-0, day-35, and day-65 isolates (directly from blood samples).

**Patient 3** is a 9-year-old African boy (weight: 53 kg) living in France who travelled during two months to Senegal in summer 2011 without antimalarial chemoprophylaxis. Two weeks after returning to France he started experiencing fever and vomiting. A peripheral blood film examination performed at the medical care unit showed *P. falciparum* (parasitemia: 6.6%). The patient was admitted to the hospital (4-day stay) and treated with 1,000 mg of atovaquone and 400 mg of proguanil, once a day for 3 days. Drug intakes (crushed tablets during the meal together with milk and plain yoghurt) were supervised. Vomiting has been reported during hospitalization. Blood film examination at day-3 post-treatment showed parasites (parasitemia: 1.2%). At the day-7 follow-up, both blood film and thick smear showed gametocytes only. At day-29 the patient presented to the hospital with fever and blood

smears showed *P. falciparum* parasites (parasitemia: 12.5%). He was admitted to the hospital (4-day stay) and as vomiting had been reported following the initial treatment he was prescribed another 3-day full course of AP. Drug intakes (crushed tablets during the meal together with milk and plain yoghurt) were supervised. During the 3-day treatment schedule, the course of the treatment was altered because of vomiting events: the patient received 5 doses instead of 3 doses of 1,000 mg of atovaquone and 400 mg of proguanil because two of them were followed by vomiting. At day-32 (day-3 follow-up after the treatment of the recrudescent infection), blood film showed trophozoites (parasitemia: 0.01%). At day-49 (day-20 after the treatment of the recrudescent infection), the patient had fever and trophozoites were detected (parasitemia: 3.5%). He was admitted to the hospital and the recrudescent infection was successfully treated with oral quinine for seven days. Parasite DNA was extracted from day-0, day-7, day-24, day-29, day-32 and day-49 isolates (either directly from blood samples or from blood smears).

**Patient 4** is a 59-year-old female weighing 64 kg. She is of African origin (native from Gabon). She is living in France since 25 years and visits Gabon every year. She travelled during 3 weeks to urban an area in Gabon during January/February 2012 without taking antimalarial prophylaxis. Twelve days after returning to France, she experienced a malaria episode with *Plasmodium* parasites evidenced on blood film examination (parasitemia: 1%) and she was treated with a full course of AP (no diet at the first dose). At day-12, no parasites were detected neither using microscopic examination nor PCR typing of peripheral blood. At day-24, the patient presented at the hospital and trophozoites were detected (parasitemia: 1%). The patient was treated again with 1,000 mg of atovaquone and 400 mg of proguanil, once a day for 3 days. At day-32 (day-8 after the treatment of the recrudescent infection), blood film and thick smear were performed and no replicating parasites were detected but gametocytes were observed. At day-46 (day-22 after the treatment of the recrudescent infection), trophozoites were detected (parasitemia: 0.2%). The second recrudescent infection was successfully treated with oral quinine for seven days. Parasite DNA was extracted from day-12, day-24, day-32 and day-46 isolates (directly from blood samples).

**Patient 5** is a 14-year-old African girl (weight: 52 kg) living in France, who travelled during one month to Ivory Coast in 2005. She declared using chloroquine as antimalarial chemoprophylaxis. Three days after returning to France she started experiencing fever with abdominal, articular and cervical pain, but without vomiting nor diarrhoea nor obtundation. A peripheral blood film examination showed *P. falciparum* parasites (parasitemia: 0.3%). The patient was admitted to the hospital for 3 days and was treated with 1,000 mg of atovaquone and 400 mg of proguanil, once a day for 3 days. The treatment however was not supervised and was later reported to be incompletely taken because of vomiting coincidentally with 2 of the 3 doses. At the day-10 follow-up, no parasites were detected using microscopic examination of peripheral blood (thin & thick). At day-23 the patient presented to the hospital with fever and vomiting which started 4 days earlier, and headaches. Blood smears showed *P. falciparum* parasites (parasitemia: 0.1%). An acute primary infection caused by

hepatitis A virus was also diagnosed concomitantly. The patient was admitted to the hospital for 4 days. With the history of vomiting during the treatment of the first malaria episode, the recrudescence infection was treated again with a standard 3-day AP treatment. Drug intakes (together with fatty food: milk and plain yoghurt) were supervised and no vomiting were observed. Symptoms disappeared during treatment. At day-31 (day-8 after the treatment of the recrudescence infection), examination of peripheral blood showed many gametocytes and few trophozoites on the thin and thick smear (parasitemia: <0.1%). The family of the patient was contacted. The patient presented to hospital on day-39: she was asymptomatic but trophozoites were detected on blood film (parasitemia: 0.25%). The patient was admitted to the hospital for 3 days and the second recrudescence infection was successfully treated with oral mefloquine (no parasites detected at days 2, 10 and 28 following mefloquine). Parasite DNA was extracted from day-0, day-23 day-31, and day-39 isolates (either directly from blood samples or from blood smears).

**Patient 6** is a 5-month-old African boy (weight: 8 kg) living in France, who travelled during two weeks to the Union of the Comoros in 2008 without taking antimalarial prophylaxis. One day after returning to France the family took him to the hospital because of fever, diarrhoea and vomiting which started three days prior. A peripheral blood film examination showed *P. falciparum* parasites (parasitemia: 4%). The patient was admitted to the hospital for 3 days and was treated with 125 mg of atovaquone and 50 mg of proguanil, once a day for 3 days. The treatment was supervised. At the day-3 follow-up, few trophozoites were detected using microscopic examination of peripheral blood (parasitemia <0.1%). At day-19 his mother took him to the hospital because of diarrhoea and fever which started on the same morning. Blood smears showed *P. falciparum* parasites (parasitemia: 6%). The patient was admitted to the hospital for 3 days and was treated with 125 mg of atovaquone and 50 mg of proguanil, once a day for 3 days. Drug intakes (crushed tablets during the meal together with milk and plain yoghurt) were supervised. At day-22 (day-3 after the treatment of the recrudescence infection), trophozoites were detected using microscopic examination of peripheral blood (parasitemia: 0.2%). A treatment with mefloquine was started, and day-26 follow-up showed gametocytes only. Parasite DNA was extracted from day-3 and day-19 isolates (directly from blood samples).

**Patient 7** is a 58-year-old male (weight: 70 kg) living in France, who experienced several *P. falciparum* malaria episodes during the last nineteen years. In 2010 he travelled during four days to Togo without taking antimalarial prophylaxis. Seven days after returning home he went to the hospital because of fever and chills without vomiting. A peripheral blood film examination performed at the hospital laboratory showed *P. falciparum* parasites (parasitemia: 2%). A standard 3-day treatment of AP was prescribed and the patient went home. At day-27 the patient presented to the hospital because of with fever and vomiting since 48 hours. Blood smears showed *P. falciparum* parasites (parasitemia: 1.5%). A standard 3-day treatment of AP was prescribed and the patient went home. At day-32 (day-5 after the treatment of the recrudescence infection), few trophozoites were detected using microscopic examination of peripheral blood (calculated parasitemia of 0.0003%, based on 13 parasites / $\mu$ L

detected on the thick smear and a measured erythrocyte concentration of 3.7 Tera/L). The patient was successfully treated with quinine during 7 days (no trophozoites detected at days 5, 13 and 28 following quinine). Parasite DNA was extracted from day-0, day-27, and day-32 isolates directly from blood samples.

We are not aware of any other AP-resistant infections, as evidenced by molecular analysis and treatment history, which have been treated with AP. However, the pattern of recrudescence following two consecutive AP treatments reported in one patient by Kuhn et al. (2005) strikingly resembles the pattern of our 7 cases reports. Unfortunately, some key genetics data were not available for this case, precluding further interpretation regarding how AP-resistant infections respond to AP. Surprisingly, we observed that a significant fraction of AP-resistant parasites were killed by AP during the first days of treatment, leading to a late treatment failure. This is a striking example as the *cytb*<sup>268</sup> mutation is the canonical single-step mutation that confers high-grade resistance to an antimalarial drug (atovaquone).

These observations could be explained by several factors, as suggested in the main discussion section. In addition, confounding factors could also have contributed to the decrease in parasitemia: 1) developing acquired immunity (not consistent with the sharp decrease observed concomitantly to treatment administration, and not consistent with similar time to recrudescence and parasitemia for the first and second failure) ; 2) concurrent intake of other compounds having antimalarial activity ; for 3 of the patients for whom relevant plasma were available (patients P1, P4 and P7), the drug dosage did not detect any additional standard antimalarial ; 3) residual drug concentrations from the first AP treatment might have resulted in higher drug concentrations when starting the second AP treatment; when available, drug dosages did not show any unusually high plasma drug concentrations.

We estimated the PRR for AP-resistant parasites to be ~50 using microscopy-derived parasite counts from 3 patients. However, caution should be taken regarding the PRR estimate we provide because 1) one patient (P3) received an altered course of AP (5 doses instead of 3 during the 3-day course of the treatment because two of them were followed by vomiting) and we cannot exclude that drug concentrations attained unusually high values, and 2) only two values of parasitemias and including day-0 (at day-0 and day-3 for patients P3 and P6, and at day-0 and day-5 for patient P7) were used to estimate the PRR and we cannot assess whether these points were in the linear portion of the parasite clearance curve nor could we take into account the lag phase (Flegg 2011, Nkhoma 2013).

### **On the origin of the mtDNA mutations conferring atovaquone resistance**

#### 1. On the atovaquone-induced mtDNA mutation hypothesis

A popular hypothesis suggests that atovaquone could have a local mitochondrial mutagenic activity through the accumulation of electrons and superoxide, as a consequence of atovaquone blocking the mitochondrial electron transport chain (Srivastava 1999). This could theoretically result in increased

frequency of resistance acquisition. One major drawback with this hypothesis is that more than one mutated copy per parasite would have to be induced, since one mutated copy per parasite is unlikely to confer high-grade atovaquone resistance. Even when considering a massive and transient burst in mtDNA mutation rate, it is very unlikely that several copies of the same parasite will be mutated simultaneously at the *cytb*<sup>268</sup> codon. Then, propagation of the atovaquone-induced mutation to daughter copies and parasites would require extensive mtDNA replication and cell division which is unlikely to occur during treatment because the high drug concentrations will likely arrest the growth of (and probably destroy) parasites carrying one or few mutated mtDNA copies. Our simulations show that asexual clonal expansion of parasites during the erythrocytic growth phase generates enough mtDNA mutations to repeatedly produce mtDNA mutant parasites before treatment initiation. In conclusion, we did not test directly the possibility of atovaquone-induced mutations. However we speculate that, if it occurred, atovaquone-induced mutagenesis would contribute marginally to the pool of mtDNA-mutated parasites produced before drug selection.

## 2. On additional notable findings

First, in one patient (P7) the presence of the 2 different mutations *cytb*<sup>Y268S</sup> and *cytb*<sup>Y268C</sup> within the day-of-failure isolates was detected (which was confirmed by cloning and sequencing of the PCR product; supplementary figure 1). This shows that at least two different mutational events occurred at the *cytb*<sup>268</sup> codon within the same host. These data confirm that mtDNA mutations can be repeatedly produced within short-term single-host infections, which is consistent with our simulations.

Second, in patient P6 the presence of the wild type genotype (*cytb*<sup>Y268</sup>) was detected in addition to the mutant *cytb*<sup>Y268C</sup> within the day-of-failure isolate. We have not yet further explored the genotypic description of this complex genotype. We predict that the presence of the wild type allele is contributed by heteroplasmic parasites (having some but not all of their mtDNA copies not mutated) rather than by wild type parasites that would have survived to AP treatment. Experiments have been designed to check this prediction.

**Table S1.** Distribution of mutant parasites and mutant alleles within infections.

	Mean	Median	Percentiles				
			5th	25th	75th	95th	99th
<b>Recessive, 20 cop, 4 cycles</b>							
Total parasite load	1.04x10 <sup>9</sup>	1.04x10 <sup>9</sup>					
≥1/20-mutant load	6	3	0	2	6	16	46
≥10/20-mutant load	0	0	0	0	0	0	4
20/20-mutant load	0	0	0	0	0	0	0
Mutation freq (x 10 <sup>-10</sup> )	9.1	2.4	0	1.0	5.3	24	100
<b>Recessive, 20 cop, 5 cycles</b>							
Total parasite load	1.24x10 <sup>10</sup>	1.24x10 <sup>10</sup>					
≥1/20-mutant load	83	58	34	46	77	156	499
≥10/20-mutant load	7	0	0	0	2	15	92
20/20-mutant load	0	0	0	0	0	0	1
Mutation freq (x 10 <sup>-10</sup> )	11.8	5.1	2.2	3.5	8.2	5.7	109
<b>Recessive, 20 cop, 6 cycles</b>							
Total parasite load	1.49x10 <sup>11</sup>	1.49x10 <sup>11</sup>					
≥1/20-mutant load	1,086	825	638	731	984	1,762	4,467
≥10/20-mutant load	117	25	5	13	55	275	1,183
20/20-mutant load	5	0	0	0	0	5	50
Mutation freq (x 10 <sup>-10</sup> )	14.4	7.5	4.6	5.9	10.6	28.7	98
<b>Recessive, 20 cop, 7 cycles</b>							
Total parasite load	1.79x10 <sup>12</sup>	1.79x10 <sup>12</sup>					
≥1/20-mutant load	13,820	11,132	9,497	10,287	12,629	20,080	49,580
≥10/20-mutant load	1,786	651	287	447	1,089	3,778	16,038
20/20-mutant load	102	6	0	2	20	168	1,150
Mutation freq (x 10 <sup>-10</sup> )	16.7	9.9	7.1	8.4	12.3	29.5	101

Data are from 20,000 simulations performed with the following parameters: recessive mutation cost, mtDNA copy number = 20, and mutation rate = 10<sup>-10</sup>/nucleotidic site/replication. ≥1/20 refers to parasites having at least one of their 20 mtDNA copies being mutated (*id est* all-mutant); ≥10/20 refers to parasites having at least 10 of their 20 mtDNA copies being mutated; and 20/20 refers to parasites having all of their 20 mtDNA copies being mutated (*id est* homoplasmic-mutant). The mutation frequency (freq) was calculated as the number of parasite mtDNA mutant copies per host divided by the total number of parasite mtDNA copies per host.


**Table S2.** Data on 26 published cases of failure of atovaquone-proguanil treatment for *P. falciparum* malaria associated with the *cytb*<sup>268</sup> mutation.

Age (year)	Country of infection	Parasitemia (%)			<i>cytb</i> <sup>268</sup> ,§		<i>dhfr</i> <sup>*,§</sup>	Ref
		d0	d <sub>fail</sub>	d <sub>fail</sub>	d0	d <sub>fail</sub>	d <sub>fail</sub>	
38	Burkina Faso	0.35	0.47	22	Y	C	3M	Musset 2006
51	Burkina Faso	nd	0.04	25	nd	S	3M	Musset 2006
36	Guinea	13	5	26	Y	S	3M	Musset 2006
55	Ivory Coast	4	5	26	Y	C	3M	Musset 2006
23	Burkina Faso/Senegal	2.8	1.5	28	Y	S	3M	Musset 2006
18	Comoros	0.5	1.3	23	Y	S	3M	Savini 2008
nd	French Guiana	nd	1	49	Y	S	3M	Legrand 2007
3.5	Mozambique	1.2	3.2	28	nd	S	nd	Rose 2008
21	India	3.4	2	34	nd	C	nd	Perry 2009
29	Sierra Leone	1.1	nd	42	nd	C	nd	Sutherland 2008
5	Nigeria	0.1	0.3	25	nd	S	nd	Sutherland 2008
30	Uganda	nd	0.2	21	nd	C	nd	Sutherland 2008
36	Uganda/Kenya	0.1	<0.1	26	Y	C	nd	Sutherland 2008
47	The Gambia	nd	3	32	nd	C	nd	Sutherland 2008
28	Cameroon	1	2.5	21	nd	S	nd	David 2003
24	Kenya	3	nd	30	Y	S	mut	Schwartz 2003
25	Sierra Leone	nd	nd	19	Y	S	2M	Kuhn 2005
45	Nigeria	1.5	<1	28	nd	N	nd	Fivelman 2002
28	Mali	nd	1.5	28	nd	S	nd	Winchmann 2004
24	Comoros	0.005	0.1	25	Y	S	3M	Current study
12	Mali	2.9	0.5	35	Y	S	3M	Current study
9	Senegal	6.6	12.5	29	Y	C	3M	Current study
59	Gabon	1	1	24	Y	C	3M	Current study
14	Ivory Coast	0.3	0.1	39	Y	S	3M	Current study
0.5	Comoros	4	6	19	Y	Y+C	3M	Current study
58	Togo	2	1.5	27	Y	C+S	3M	Current study

\*, d0 and d<sub>fail</sub> refer to day of diagnosis and day of failure, respectively;

§, The mutations *cytb* Y268S and Y268C confer resistance to atovaquone; 2M and 3M refer to double and the triple *dhfr* mutations, respectively, that confer resistance to cycloguanil.

**Supplementary figure 1. Presence of the 2 *cytb* mutations Y268S and Y268C within the day-22 isolate from patient P7.** Sequences shown in Suppl\_1B and suppl\_1C were obtained from different clones of the same PCR product.





### **Supplementary references:**

David KP et al. (2003) Atovaquone/proguanil resistance in Africa: a case report. *Scand J Infect Dis.* 35(11-12):897-8.

Fivelman Q L et al. (2002) Malarone treatment failure and in vitro confirmation of resistance of *Plasmodium falciparum* isolate from Lagos, Nigeria. *Malar J.* 1:1.

Flegg JA et al. (2011) Standardizing the measurement of parasite clearance in *falciparum* malaria: the parasite clearance estimator. *Malar J.* 10:339.

Kuhn S et al. (2005) Emergence of atovaquone-proguanil resistance during treatment of *Plasmodium falciparum* malaria acquired by a non-immune north American traveller to west Africa. *Am J Trop Med Hyg.* 72(4):407-9.

Legrand E, et al. (2007) First case of emergence of atovaquone resistance in *Plasmodium falciparum* during second-line atovaquone-proguanil treatment in South America. *Antimicrob Agents Chemother* 51(6):2280-2281.

Musset L, Bouchaud O, Matheron S, Massias L, & Le Bras J (2006) Clinical atovaquone-proguanil resistance of *Plasmodium falciparum* associated with cytochrome b codon 268 mutations. *Microbes Infect* 8(11):2599-2604.

Nkhoma SC et al. (2013) Genetic evaluation of the performance of malaria parasite clearance rate metrics. *J Infect Dis.* 208(2):346-50.

Perry TL et al. (2009) Severe atovaquone-resistant *Plasmodium falciparum* malaria in a Canadian traveller returned from the Indian subcontinent. *Open Med.* 3(1):e10-6.

Rose GW et al. (2008) Atovaquone-proguanil resistance in imported *falciparum* malaria in a young child. *Pediatr Infect Dis J.* 27(6):567-9.

Savini H, et al. (2008) First case of emergence of atovaquone-proguanil resistance in *Plasmodium falciparum* during treatment in a traveler in Comoros. *Antimicrob Agents Chemother* 52(6):2283-2284.

Schwartz E, Bujanover S, & Kain KC (2003) Genetic confirmation of atovaquone-proguanil-resistant *Plasmodium falciparum* malaria acquired by a nonimmune traveler to East Africa. *Clin Infect Dis* 37(3):450-451.

Srivastava IK et al. (1999) Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites. *Mol Microbiol.* 33(4):704-11.

Sutherland CJ, et al. (2008) Mutations in the *Plasmodium falciparum* cytochrome b gene are associated with delayed parasite recrudescence in malaria patients treated with atovaquone-proguanil. *Malar J* 7:240.

Wichmann O, et al. (2004) Screening for mutations related to atovaquone/proguanil resistance in treatment failures and other imported isolates of *Plasmodium falciparum* in Europe. *J Infect Dis.* 190(9):1541-6.